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Real-time PGR 檢測了 let 7a，miR-122a，miR-221 等三種 miRNAs 在一系列肝 
癌細胞中的表達情況。我們觀察到相對于永生化的MIHA細胞，這三種miRNAs 






















In recent years, a new class of small RNAs, microRNAs (miRNAs), has aroused 
intense interest among the scientific community. They are short non-coding RNA 
molecules that inhibit gene expression through incomplete base pairing with the 
3'-untranslated region of target mRNAs. miRNAs have been implicated in critical 
processes including differentiation, apoptosis, proliferation, and the maintenance of 
cell and tissue identity, furthermore, their misexpression has been linked to cancer 
and other diseases. Till now hundreds of miRNAs have been identified and predicted 
to regulate thousands of genes in mammals, but relatively few targets have been 
experimentally validated and few miRNA gain-of-function phenotypes have been 
assigned. 
In this research, we are interested in HCC-associated miRNAs. First we 
analysed the expression level of three miRNAs-let 7a,miR-122a and miR-221 in a 
series of HCC cells by miRNA-specific quantitative Real-time PGR. We identified 
the down-regulation of miR-122a and the up-regulation of miR-let7a，miR-221 in 
Hep3B,Bel 7404 and HepG2 cells compared to the immortalized liver cell MIHA. Of 
the three miRNAs tested, we mainly focused on miR-122a, the liver specific miRNA. 
Since analysis of miRNA function requires methods to generate stable gain-and 
loss-of-function phenotypes for individual miRNAs, the construction of a lentiviral 
vector had obvious advantages which also facilitated subsequent identification and 
isolation of modified cells. Our miRNA expression vector was based on an RNAi 
expression system in which the expression of shRNAs is driven by a U6 promoter 
whereas the neomycin resistance gene and EGFP were bicistronically expressed by a 
CMV promoter. The expression of EGFP allowed for convenient monitoring of the 
infection efficiency under a fluorescent microscope. We designed a Lentiviral vector 
for ectopic overexpression of miR-122a. Successful construction of this vector 
provided us with an efficient and inexpensive way for introduction of the miRNAs 
into cultured cells which may facilitate the gain-of-function study for certain 
miRNAs. With this efficient vector, we have observed the effect of miR-122a in 
HCC cell growth inhibition as well as induction of apoptosis. 
ii 
ABSTRACT 
To begin unraveling the potential role of miR-122a in hepatocarcinogenesis, we 
utilized bioinformatic approaches for the target prediction. By using combinations of 
two algorithms, Target Scan and Pic Tar, 98 potential targets have been suggested, of 
which their functions are related to signal transduction, cell cycle, cell proliferation 
and differentiation, cell adhesion, cell communication and so on. To validate the 
predicted miRNA targets, we further utilized two-dimensional gel electrophoresis, 
the leading tool in proteomics research. 16 differentially expressed proteins (spots) 
with at least 3-fold change have been identified between cells transducted with 
control vector and cells transducted with the miR-122a expressing vector. 
Identification of the proteins by MALDI-TOF MS revealed eleven differentially 
expressed proteins, among which proteasome activator subunit 1 isoform 1 
(PA28alpha) and beta polypeptide 2-like 1 (GNB2L1) were upregulated in miR-122a 
treated HCC cells. Since they are reported to be downregulated in HCCs and 
involved in the onset of hepatocarcinogenesis, the phenotype change of HepG2 
caused by overexpression of miR-122a may take effect through these two proteins. 
That is, PA28alpha and GNB2L1 may present two potential targets for miR-122a 
which will be further confirmed by other means, ie. western blot. 
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Introduction and Background 
In recent years, a new class of small noncoding RNAs,miRNAs (miRNA), has 
been discovered in animals and plants which has aroused intense interest among 
scientific community. Although the first miRNA was identified more than ten years 
ago, it is only recently that scientists have begun to understand the importance of 
these small molecules. 
miRNAs are short non-coding RNA molecules that inhibit gene expression either 
through incomplete base pairing with the 3'-untranslated region (3'-UTR) of target 
mRNAs or directly degrade target mRNAs through complete base pairing of which 
the former seems to be the primary mode of action \ In mammals, hundreds of 
miRNAs have now been identified . For the few miRNAs whose function have been 
uncovered, they are important regulators of various aspects of developmental 
control. i，2.Since the inception of this regulatory RNA phenomenon, much progress 
has been made towards an understanding of the mechanisms by which this occurs 
1.1 General introduction to miRNA 
1.1.1 The discovery and biogenesis of miRNA 
1.1.1.1 The discovery of micro RNA 
The first miRNA was discovered in 1993 by Victor Ambros and colleagues 
Rosalind Lee and Rhonda Feinbaum.4 They discovered that in C.elegans, lin-4 
produced a pair of short RNA transcripts instead of coding for a protein. And each of 
the short transcripts regulates the timing of larval development by translational 
repression of lin-14, which encodes for a nuclear protein. Seven years later, Reinhart 
et al. discovered let-7, another small RNA of this type, which was also involved in C. 
elegans developmental timing. ^ Within the following year, more than 100 additional 
small regulatory RNAs similar to lin-4 and let-7 were identified in worms, the fruit 
fly Drosophila, and in humans .These small non-coding RNAs were named 
microRNAs (miRNAs).Till now thousands of miRNAs have been identified in 
organisms as diverse as viruses, worms, and primates. 
1.1.1.2 The biogenesis of miRNA 
The biogenesis of miRNA is a stepwise maturation process. Figure 1 shows the 
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current understanding of the biogenesis of miRNA. The process begins with the 
transcription of a miRNA gene by polymerase II to form primary miRNA 
(pri-miRNA) which possess a 5' 7-methyl guanosine cap and are polyadenylated 
9’ 10 .Then the pri-miRNA is processed by a RNase III endonuclease named Drosha to 
produce pre-miRNAs ,which fold into stem-loop structures of �70 nucleotides in 
length.The pre-miRNAs are then transported to the cytoplasm by Exportin-5 in a Ran 
GTPdependent manner . In the cytoplasm, a second RNase III endonuclease named 
Dicer cleaves the loop of pre-miRNA and the ~22 nt double stranded RNA are 
formed. One strand of the miRNA duplex is subsequently incorporated into an 
effector complex termed RNA-induced silencing complex that mediates target gene 
expression. Depending on the level of complementarity between the miRNA and the 
target sequence, the mRNA can either be translationally repressed or cleaved ii’i2’i3’3 
In plants, cleavage appears to be the primary mode of action, while in mammals 
translational repressions seems to be the key method 
^ i Nucleus Cytoplasm 
Pri-miRNA 
( , : 
V �� . . . 




Figure 1.1 Model of miRNA biogenesis. Long primary transcripts 
(pri-miRNAs) containing one to several miRNAs are generated by 
polymerase II and are5'capped and polyadenylated. The recently identified 
Microprocessor complex, comprising Drosha (Rnase III endonuclease) and 
DGCR8 (a double-stranded RNA binding protein) recognize the distinct 
hairpin secondary structure of the pri-miRNA and specifically cleave at the 
base of the stem loop releasing a 60- to 70-nucleotide pre-miRNA 
intermediate enabling Exportin 5-mediated cytoplasmic export where Dicer, 
a second RNase III endonuclease, cleaves 22-nucleotide from the Drosha 
cleavage site to yield the mature miRNA.‘ 
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1.1.2 The function of miRNA 
Till now, several hundred miRNAs have been indentified, however, the biological 
role and in vivo functions of most miRNAs are still poorly understood, only a 
handful have known functions \ In invertebrates, miRNAs have been implicated in 
developmental timing, neuronal differentiation, cell proliferation, growth control, and 
programmed cell death I5’i6’4 工打 mammals, miRNAs have been found to play a role 
in embryogenesis and stem cell maintenance 口，hematopoietic cell differentiation'^, 
and brain development What's more, miRNAs expression has been found to be 
deregulated in a wide range of human diseases including cancer suggesting their 
roles in pathological processes. 
1.1.2.1 miRNAs in development and differentiation 
The first two miRNA—lin-4 and let-7 were discovered through developmental 
screens in C. elegans.Besides these two, some other miRNAs are also involved in 
development of higher organisms including mammals.Table 1.1 shows roles of 
miRNAs in development. The downregulation of a set of stem cell specific miRNAs 
during differentiatio suggests the role of miRNAs during early stages of development. 
Suh MR. et al described 36 miRNAs identified by cDNA cloning in hES cells，most 
of which were specifically expressed in hES cells and downregulated during 
development into embryoid bodies (EBs) Other examples for developmental 
roles of miRNAs include regulation of B- lymphocyte and myoblast differentiation 
by miR-181 insulin secretion by miR-375 liver development and function by 
miR-122a ^^  and adipocyte differentiation by miR-143^^ 
Name of miRNA Function Target gene 
Lin-4 C. elegans development Lin-14, lin-28 
Let-7 C. elegans development Lin-14, lin-28, 
Lin-41,l in-42,daf-12^ 
miR-1 Cardyomyocyte differentiation HDAC4 ,Myostatin 
miR-196 Embryo patterning H0XD8 
miR-34 Dendritic spine development Limkl 
miR-133b Maturation of dopaminergic neurons Pitx3 
miR-181 B lymphocyte differentiation Not known 
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Myoblast differentiation HOX-All 
miR-375 Insulin secretion Myotrophin 
miR-122a Liver development and function Many genes 
miR-143 Adipocyte differentiation ERK5 
Table 1.1 Roles of microRNAs (miRNAs) in development 27 
1.1.2.2 The potential role for miRNAs in cancer 
Cancer is a very complex genetic disease characterized by alterations in genes 
encoding oncogenic and tumor-suppressor proteins. All types of cancers share a 
number of characteristics, including the loss of cellular identity, an increased ability 
of proliferation, and alterations in the systems controlling cell death. Studies 
performed in a variety of organisms have revealed the ability of miRNAs to 
regulate these cellular processes, suggesting their implication in carcinogenesis^^. 
Emerging data indicate that dysregulation of miRNAs is associated with certain types 
of cancer. Table 1.2 shows several miRNAs involved in different types of cancers. 
Althoug their mechanism of action as well as their importance in cancer is not yet 
fully understood, they may provide an important layer of genetic regulation in 
，Q 
tumorigenesis, and ultimately become valuable therapeutic tools . 
Name of miRNA Up or down Type of cancer Target gene 
regulation 
miR-15, 16 Down chronic BCL2 
lymphocytic 
leukaemia 
Let-7 Down Lung RAS, MYC 
miR-17-92 cluster Up Lm^ PTEN，RB2 
miR-221,222, 146 Up papillary S T 
thyroid 
carcinoma 
miR-143, 145 Down colorectal Not known 
neoplasia 
miR-21,125b, Down Breast Not known 
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• 145, 155 
miR-21,221 Up Gliobastoma Not known 
multiforme 
miR-181 down Gliobastoma Not known 
multiforme 
miR-155 Up B-cell Not known 
lymphoma 
miR-17-92 cluster Not known Not known Tspl, CTGF 
miR-lOb Up Metastatic HOXDIO 
breast cancer 
Table 1.2 miRNAs involved in different types of cancers^^ 
1.2 The liver-specific miRNA : miR-122a 
1.2.1 Discovery and biogenesis of iniR-122a 
In 1989, when studing on genetic alterations in woodchuck liver, Moroy T. et al. 
discovered a gene rearrangement of c-myc and an unusual transcript, named her, in 
one of these tumors. This transcript was characterized as liver specific, essentially 
，Q 
non-coding, specifically nuclear, and processed by endonucleases . Further, her was 
proposed to be the precursor for miR-122a and was identified as an abundant miRNA 
in the liver by systematic cloning and sequencing of small RNAs prepared from 
different mouse tissues in 2002 . miR-122a was further characterized as the most 
frequent miRNA isolated in the adult liver, which accounts for 70% of the total liver 
miRNA population ^^miR-122a is found in mouse, woodchuck and human livers, in 
human primary hepatocytes, and in cultured liver-derived cells ’ . 
1.2.2 miR-122a, a liver specific miRNA 
1.2.2.1 miR-122a amongst other liver-expressed miRNAs 
Muriel Girard et. al compiled the relative expression levels of miRNAs that were 
specially expressed in human liver]*. While miR-92a and miR-483 seem to be more 
specifically expressed in the fetal liver，miR-122a appears as the most highly 
expressed miRNA in adult liver. Thus, in the search for miRNA-deregulated 
pathways involved in liver diseases, miR-122a serves as an interesting candidate. 
1.2.2.2 Overall role of miR-122a in human liver 
miR-122a plays an important role in liver physiology which is supported by the 
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fact that miR-122a is specifically expressed in normal liver, accounting for 70% of 
the total liver miRNA population in human. Hence, it is conceivable that its 
deregulation may have a significant effect on various liver functions^^.In the search 
for an effective way to silence miR-122a, two research groups, Krutzfeldt et al. and 
Esau et al. had both found the overall importance of miR-122a in the regulation of 
metabolism ’ .They discovered that several genes that regulate lipid metabolism, 
specifically the key enzyme phosphomevalonate kinase, were down-regulated In 
both studies, silencing miR-122a resulted in a notable decrease of plasma cholesterol 
levels, which was consistently associated with decreased expression of genes 
involved in cholesterol biosynthesis^^. miR-122a has diversity of roles in human liver. 
It was also found to be actively involved in cellular stress response, 
hepatocarcinogenesis and replication of the hepatitis C virus^''^^"^^. 
1.2.3 miR-122a and Hepatocellular carcinoma (HCC) 
1.2.3.1 Downregulation of miR-122a in HCC 
Hepatocellular carcinoma (HCC) accounts for approximately 85% of liver 
cancers and it is one of the most prevalent carcinomas throughout the world which is 
the third leading cause of death from cancer 39. 
Down-regulation of miRNAs was observed in the majority of HCCs and 
HCC-derived cell lines suggesting that they might play an important role in 
hepatocarcinogenesis"^®. 
With the help of miRNA microarray platform, several research groups have 
identified the miRNAs that are differentially expressed in HCC compared to normal 
liver tissue 4i’42 . Laura Gramantieri et. al reported a comprehensive analysis of 
miRNA expression in HCCs arisen on liver cirrhosis (LC).According to their data, 
thirty-five miRNAs emerged as differentially regulated in HCC tissue with respect to 
cirrhosis, such as members of the let-7 family, mir-221, mir-145 and strikingly, the 
hepato-specific miR-122a was found downregulated in about 70% of HCCs and in 
all HCC-derived cell lines"^ .^ In Huban Kutay's research, the downregulation of 
miR-122a was found in both rodent and human hepatocellular carcinomas. Their 
study in human primary HCCs showed that miR-122a expression was significantly 
reduced in 10 out of 20 tumors compared to the pair-matched control tissues'^'. These 
findings suggest that the downregulation of miR-122a is associated with 
hepatocarcinogenesis and could be a potential biomarker for liver cancers. 
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1.2.3.2 miR-122a in the pathogenesis of Hepatocellular carcinoma 
miR-122a was reported to be significantly and specifically down-regulated in 
hepatocarcinoma (HCC) in humans. Amongst the putative target genes of miR-122a 
indentified using bioinformatic approaches, at least three are implicated in 
tumorigenesis. N-Myc, which is frequently rearranged in woodchuck liver tumors by 
woodchuck hepatitis virus, provides either a significant proliferative stimulation 
and/or a growth advantage in hepatocarcinogenesis of woodchucks with chronic 
WHV infection43. DRLM, the gene referred to as "down-regulated in liver 
malignancy" which showes loss or extreme decrease of expression in five of 13 HCC 
cell lines, is suggested to play an important role in human hepatocarcinogenesis 44. In 
2007, Laura Gramantieri et. al revealed that Cyclin G1 was a target of miR-122a. 
miR-122a can modulate cyclin G1 expression in HCC-derived cell lines and an 
inverse correlation between miR-122a and cyclin G1 expression in primary liver 
carcinomas was further observed 42. In experimental hepatocarcinogenesis, loss of 
cyclin G1 is associated with a significantly lower tumor incidence after carcinogenic 
challengers. 
1.2.4 Therapeutic opportunities and challenges of miR-122a 
Recognizing the miRNAs that are deregulated in human HCCs represents the 
first step for the development of experimental therapies of this type. miR-122a, the 
liver-specific miRNA frequently down-regulated in human hepatocellular carcinoma 
represents a good candidate for miRNA-mediated therapy. In addition, since liver can 
be effectively targeted by in vivo delivery of short RNAs, it represents a good model 
for the development of anticancer miRNA-based approaches of gene therapy^ '^"* .^ 
Synthetic analogues of miRNA have already been employed to specifically regulate 
gene function in mice ’ . One potential therapeutic application comes from the 
effect of miR-122a antagomir, by using the cholesterol-conjugated single-stranded 
RNA molecules, Krutzfeldt J et. al successfully inhibited the expression of miR-122a, 
and reduced plasma cholesterol levels as well as a decrease in the rate of hepatic fatty 
acid and cholesterol synthesis were observed in normal and dietinduced obese mice. 
It's just six years ago when natural miRNA was first discovered to be functional in 
humans47. while the pace of discovery in this field is so fast that increasing rationale 
has been provided for manipulating miRNAs therapeutically"^^.Given the broad 
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effects of miR-122a in the liver, and the number of miRNAs, there's no doubt that 
many noval and unanticipated roles of miRNAs in the control of normal and 
abnormal liver function are awaiting discovery. 
1.3 Techniques and approaches to study miRNAs 
1.3.1 Discovery of novel miRNA 
The discovery of novel miRNAs can be achieved by means of both experimental 
methods and bioinformatics approaches. By forward genetics methods, the first two 
miRNA genes- lin-4 and let-7 were identified in C.elegance. However, this approach 
seems unlikely to be a main tool due to the relative inefficiency of miRNA gene 
discovery. More and more miRNAs were discovered by cloning all small RNAs from 
a certain tissue type or developmental stage and subsequent sequencing to identify 
the subgroup of small RNAs that fulfill the criteria for miRNAs'^^. After initial 
cloning efforts generated sufficient information about miRNA properties to recognize 
a set of distinctive miRNA features, bioinformatics approaches surveying genomic 
sequences to predict miRNAs became popular^^. Numerous approaches to miRNA 
prediction have been developed and can be categorized on the basis of the particular 
miRNA features that they use for prediction, such as conservation of potential target 
sequences, thermodynamic stability of secondary structure similarity to known 
miRNAs and so on. Till now, thousands of miRNA have been discovered by various 
means. All known miRNAs are registered in a public web-based registry, the 
"miRBase" database that provides up-to-date information on all published miRNAsS� 
Both computational and experimental approaches indicate that many more miRNAs 
are likely to be identified^ '^"^ ,^ which is reflected by the rapidly increasing number of 
annotated miRNAs increasing from less than 300 to more than 4,000 over the past 
four years. 
1.3.2 Detection of miRNA 
Northern blot analysis, a well-established technique for studying messenger RNA 
expression was adapted to be the first detection method used in the quantification of 
miRNAs4’53. Northern blot is currently considered as the gold standard for miRNA 
detection. It has the advantage of simultaneously detecting the precursor and mature 
miRNAs, however, it is inherently insensitive and requires a relatively large amount 
of RNA sample. Over the past years, a number of different approaches have been 
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described to quantify miRNAs including miRNA microarray, modified Invader assay, 
real-time reverse transcriptase-polymerase chain reaction(RT-PCR) and confocal 
laser-induced fluorescence detection etc^" '^^ .^Among the methods mentioned above, 
real-time RT-PCR and miRNA microarray and have been commonly used for the 
detection of miRNA. The real-time RT-PCR method makes use of a stem-loop 
reverse transcription primer to generate cDNA templates,which are then amplified 
using specific primers and detected with specific fluorescence probes, similar to the 
standard real-time RT-PCR for the detection of mRNA. Real-time PGR has been 
widely used in miRNA quantitation for its unparalleled sensitivity and specificity. 
However, the method is inefficient when comes to large-scale screening. For this 
purpose, miRNA microarray was modified from conventional DNA microarray 
technology which is capable for the simultaneous analysis of hundreds of miRNAs 
present in a single sample. Development of this technique has greatly facilitated the 
analysis of miRNA expression patterns for a large number of samples^^'^^.Recently, 
methods have been developed to localize miRNA expression at the cellular and 
subcellular levels by in situ hybridization which allows determination of expression 
in single cells within a heterogenous cell population and facilitates comparison of 
miRNA expression in different cell populations in their natural contexts without the 
need of cell sorting or separation. This method is well suited for evaluating clinical 
archived samples and thus is particularly useful for advancing miRNA research in 
pathology58. 
1.3.3 Functional study of miRNAs 
To investigate the function of miRNAs, various strategies have been developed. 
For loss-of-function studies, modified antisense oligonucleotides have been 
generated to knockdown certain miRNAs or pre-miRNAs which allow us to draw 
conclusions regarding possible physiological functions of miRNAs from the resulting 
abnormal phenotype^^'^®. 2'-0-methyl oligonucleotide was the first modified 
antisense oligonucleotides to specifically knock down certain miRNAs . In C.elegans, 
injection of the 2'-0-methyl oligonucleotide complementary to the miRNA let-7 can 
induce a let-7 loss-of-function phenocopy, and further study shows that the C. 
elegans Argonaute proteins ALG-1 and ALG-2, are constituents of a let-7-containing 
protein-RNA complex^®. When it comes to human, the inhibition of human 
micro-RNA miR-125b using 2'-0-methyl oligonucleotide reveals that the miRNA is 
critical for the proliferation of differentiated cells but not for the down-regulation of 
- 9 -
putative targets during differentiation ^^LNA-modifled antisense oligonucleotides 
have also been successfully utilized to knock down specific miRNAs in cultured 
cells. This approach allowed identification of a crucial role for miR-223 in 
granulocytic differentiation^^.Besides, a novel class of chemically engineered 
oligonucleotides, termed 'antagomirs', is able to inhibit miRNA function in the 
adult mouse which provides a potential research tool to study miRNA function in 
vivo25. For gain-of- function studies, things are much easier, chemically synthesized 
miRNA presursor molecule which are designed to mimic endogenous mature miRNA 
or "mimics" directely are both able to increase miRNA expression. In addition, stable 
gain-of-function can be achieved by overexpressionof individual miRNAs upon 
retro-or lentiviral transfer of suitable miRNA-expression cassettes"^ '^^ "^^ "^ . 
1.3.4 Prediction and validation of miRNA targets 
The accurate prediction and validation of genes targeted by miRNAs is currently 
a major challenge in miRNA biology. In contrast to the identification and validation 
of thousands of miRNA genes, the experimental evidence identifying their 
corresponding mRNA targets remains limited. An increasing number of sophisticated 
bioinformatics approaches are being utilized to predict putative miRNA target 
genes.And various computational algorithms have been developed for the purpose, 
among which miRanda(http://microma.sanger.ac.uk)^'; TargetScan (http:// www. 
targetscan.org) 65’66，67，肌d PicTar (http://pictar.bio.nyu.edu) 68,69 are suggested to 
have higher performance values?�. Although bioinformatics approaches can predict 
thousands of genes that are potentially targeted and regulated by miRNAs based on 
sequence complementarity, only very few miRNA target genes have been 
functionally validated.And what's more, since exact base pairing between miRNAs 
and their targets commonly appears to be required only in the first six to eight bases 
from the 5' end of the miRNA, target prediction by bioinformatic approach tends to 
cause a relatively higher level of both false-positive and false-negative results. It is 
clear that experimental validation of predicted miRNA targets is critically important 
in order to confirm any putative miRNA-target gene combination. The most 
commonly used methods for miRNA target validation is to express a miRNA in vivo 
while simultaneously expressing and monitoring the target messenger RNA linked to 
a reporter gene, for example, Luciferase^^'^^.A different approach to discovering 
miRNA target genes is to knock out or overexpress a particular miRNA and turn to 
proteomics for analysing the changes at protein level.Or, we can use conventional 
- 1 0 -
microarrays to identify genes that show changes in expression. This approach is 
based on the observation that some miRNAs can also downregulate messenger RNA 
levels in addition to downregulating protein levels of their target genes . 
- 1 1 -
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Materials and methods 
2.1 Cell culture. 
HCC cell lines (MIHA，Hep3B，Bel 7404，HepG2) were cultured with Dulbecco's 
Modified Eagle's Medium supplemented with 10% fetal bovine serum and 100 
units/ml of penicillin G sodium, and lOOg/ml streptomycin sulfate in a humidified 
atmosphere containing 5% CO2 at 37 °C. 
2.2 Cell transfection 
Mature miRNA mimics has-mir-122a (CatttC-300094-01-0005) and Mimic 
Negative Control (Cat# CN-001000-01-05) were purchased from DHARMACON. 
The day before transfection, HCC cells were seeded in antibioticfree medium. 
Transfection of miRNAs was carried out using Lipofectamine 2000 in accordance 
with the manufacturer's procedure (Invitrogen). The level of miR-122a expression in 
transfected HCC cell line was assayed by real-time RT-PCR (Taqman MicroRNA 
Assays) 48 h after transfection. 
2.3 RNA extraction 
Cells were lysed by adding appropriate amount of TRIzol Reagent and the cell 
lysate were passed through a pipette several times. Incubate the homogenized 
samples for 5 minutes at 15 to 30°C to permit the complete dissociation of 
nucleoprotein complexes. Add 0.2 ml of chloroform per 1 ml of TRIzol Reagent. Cap 
sample tubes securely. Shake tubes vigorously by hand for 15 seconds and incubate 
them at 15 to 30°C for 2 to 3 minutes. Centrifuge the samples at no more than 
12,000 X g for 15 minutes at 4°C .Transfer the aqueous phase to a fresh 
tube. Precipitate the RNA from the aqueous phase by mixing with isopropyl 
alcohol. Use 0.5 ml of isopropyl dcohol per 1 ml of TRIzol Reagent used for the 
initial homogenization. Incubate samples at 15 to 30°C for 10 minutes and centrifuge 
at no more than 12,000 x g for 10 minutes at 4 °C. The RNA precipitate forms a 
gel-like pellet on the side and bottom of the tube.Remove the supernatant. Wash the 
RNA pellet once with 75% ethanol, adding at least 1 ml of 75% ethanol per 1 ml of 
TRIzol Reagent used for the initial homogenization. Mix the sample by vortexing 
and centrifuge at no more than 7,500 x g for 5 minutes at 2 to 8°C. At the end of the 
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procedure, briefly dry the RNA pellet (air-dry for 5-10 minutes) and dissolve it in 
appropriate amount of DEPC-treated water. 
2.4 Plasmid extaction 
Plasmid extraction were performed by using QIAGEN Plasmid Extraction Maxi 
Kit (Cat#12162) Pick a single colony from a freshly streaked selective plate and 
inoculate a starter culture of 2-5 ml LB medium containing the appropriate selective 
antibiotic. Incubate for approx. 8 h at 37°C with vigorous shaking (approx. 300 rpm). 
Dilute the starter culture 1/500 to 1/1000 into selective LB medium. Grow at 37°C 
for 12-16 h with vigorous shaking (approx. 300 rpm). Harvest the bacterial cells by 
centrifugation at 6000 x g for 15 min at 4°C. Resuspend the bacterial pellet in 10 ml 
Buffer PI. Add 10 ml Buffer P2, mix thoroughly by vigorously inverting the sealed 
tube 4-6 times, and incubate at room temperature for 5 min. Add 10 ml of chilled 
Buffer P3, mix immediately and thoroughly by vigorously inverting 4 - 6 times, and 
incubate on ice for 20 min. Centrifuge at 9,000rpm for 30 min at 4° C. Remove 
supernatant containing plasmid DNA promptly. Centrifuge the supernatant again at 
9，000rpm for 15 min at 4° C. Remove supernatant containing plasmid DNA 
promptly. Equilibrate a QIAGEN-tip 500 by applying 10 ml Buffer QBT, and allow 
the column to empty by gravity flow. Apply the supernatant to the QIAGEN-tip and 
allow it to enter the resin by gravity flow. Wash the QIAGEN-tip with 2x 30 ml 
Buffer QC. Elute DNA with 15 ml Buffer QF. Precipitate DNA by adding 10.5 ml 
(0.7 volumes) room-temperature isopropanol to the eluted DNA. Mix and centrifuge 
immediately at 9，000rpm for 30 min at 4°C. Carefully decant the supernatant. Wash 
DNA pellet with 5 ml of room-temperature 70% ethanol, and centrifuge at 9,000rpm 
for 10 min. Carefully decant the supernatant without disturbing the pellet. Air-dry the 
pellet for 5-10 min, and redissolve the DNA in a suitable volume of TE buffer, pH 
8.0. 
2.5 Competent cell preparation 
Pick a single colony from a freshly grown plate of E. coli and disperse it into 2ml 
of LB,shake at 37°C for 16h.Dump the culture into 250mL of LB,grow cells at 37°C 
with vigorous shaking for approximately 3 hours. Cell density is monitored by 
determining OD600 and should be less than 10 ^ cells / ml (log phase of growth - the 
most healthy bacteria). Pellet the cells at 5,000 rpm for lOmin at 4°C.Add 250mL 
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buffer I to the pellets and resuspend cells.Sit on ice for 5min.Spin again at 5,000rpm 
for lOmin at 4°C.Add 12.5mL of buffer II and resuspend the cells.Sit on ice for 
15min.Aliquot 200ul into Eppendorf tubes.Store at -80°C. 
Buffer I : For 250mL 
MES 10 mM,pH 5.8 5mL of 0.5M MES buffer 
RbCb 100 mM 3.02 gram 
CaCl2 10 mM 5ml of 0.5M CaCb solution 
MnCl2 50 mM 2.47gram 
BufferII:For50mL 
PIPES lOmM, pH 6.5 5ml of 0.1 M PIPES buffer 
CaCb 75mM 7.5ml of 0.5M CaCb solution 
RbCb lOmM 61mg 
Glycerol 15% 
MES buffer pH 5.8: 
9.76 gram of MES in 100ml H2O,adjust pH with NaOH 
PIPES buffer pH 6.5 
3.463 gram of PIPES Na in 100ml，adjust pH with HCl 
CaC12 solution 0.5M 
14.7 gram ofCaCl2.2H20 in 200 ml of H2O 
MES: 2-(N-morpholino)ethanesulfonic acid 
PIPES: pipenazine-N,. N'-bis. (2-ethanesulfonic. acid). 
MOP: 3 -(N-Morpholino)propanesulfonic acid 
Rb: rubidium 
2.6 Bacterial Transformation: 
Pipette 200ul competent cells into Eppendorf tubes. Add lul plasimd and place 
the tubes on ice for 30 min. Put the tubes at 42°C for exactly 90 seconds. Return the 
cells to ice for 1-2 minutes. Add 0.5ml LB(without antibiotics) into the tube and mix 
several times, shake and incubate at 37°C for 45min. Pipette the transformation 
mixtures onto labeled plate containing ampicillin and spread them around using a 
sterilized, bent glass rod spreader. Place upside down in the 37 °C incubator 
overnight. 
2.7 Purification of DNA fragments from agarose gel 
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Excise the DNA fragment from the agarose gel with a clean, sharp scalpel.Weigh 
the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume of gel. 
Incubate at 50°C until the gel slice has completely dissolved. To help dissolve gel, 
mix by vortexing the tube every 2-3 min during the incubation.After the gel slice has 
dissolved completely,add 1 gel volume of isopropanol to the sample and mix if DNA 
fragments <500 bp and >4 kb.Place a QIAquick spin column in a provided 2 ml 
collection tube.To bind DNA, apply the sample to the QIAquick column, and 
centrifuge for 1 min.Discard flow-through and place QIAquick column back in the 
same collection tube. Add 0.5 ml of Buffer QG to QIAquick column and centrifuge 
for 1 min.To wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 
1 min.Discard the flow-through and centrifuge the QIAquick column for an 
additional 1 min at 13,000 rpm. Place QIAquick column into a clean 1.5 ml 
microcentrifuge tube.To elute DNA, add 50 i^l of Buffer EB (10 mM Tris-Cl, pH 8.5) 
to the center of the QIAquick membrane,let the column stand for 1 min, and then 
centrifuge for 1 min. 
2.8 Genomic DNA extranction from MIHA cell 
Wash the cell with 1 X PBS and harvest the cells from 10cm dish by 
trypsinization.Resuspend the cell in 400ul of lysis buffer (50mM Tris-Cl pH 8.0， 
0.5% SDS lOmM EDTA).Add 4ml of proteinase K(20mg/ml) to sample (final 
concentration 200ug/ml) ,mix and incubate at 55 "C for 2h.Add 0.8ul of RNase 
A(10mg/ml) to sample (final concentration 20ug/ml) mix and incubate at 37°C for 
lh，add NaCl to final concentration of 0.2M. Extract twice with phenol: 
chloroform(l:l) (200ul:200ul) and once with chloroform (400ul). Add 1ml ofEtOH 
and 0.1 volume of 3M NaAcetate (PH 5.0)，incubate at -20°C for 30min.Centrifuge 
for 10 min.Add 1 ml of 70% EtOH to wash the pellet. Dry the pellet and resuspend 
the pellet in TE or dHzO,heating at 65 °C for 10 min. Measure the concentration 
A260/A280 ratio should be around 1.9 and run gel to check. 
2.9 Real-time RT-PCR analysis. 
The expression of mature miRNAs was assayed using the Taqman MicroRNA 
Assays (Applied Biosystems) specific for hsa-mir-122a (P/N: 4373151), hsa-let-7a 
(P/N: 4373169)，and hsa-mir-221 (P/N: 4373077) on normal liver cell and a series of 
HCC cells. The expression level of miR-122a was measured also in HepG2 cells 
transfected with miR-122a (DHARMACON). Each sample was analyzed in triplicate. 
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lug of total RNA was used for reverse transcription reaction using the specific 
looped primers. Real-time PGR was done according to the standard Taqman 
MicroRNA Assays protocol on the Applied Biosystems 7500 Real-Time PGR System 
(ABI). The 20 ul PGR included 1.33 ul reverse transcription product, 1 xTaqman 
Universal PGR Master Mix, No AmpErase UNG (P/N 4324018; Applied 
Biosystems), 0.2 umol/L Taqman probe, 1.5 umol/L forward primer, and 0.7 umol/L 
reverse primer. The reactions were incubated at 95 °C for 10 min followed by 40 
cycles of 95 °C for 15 s and 60 °C for 1 min. The level of miRNA expression was 
measured using Ct (threshold cycle). The Ct is the fractional cycle number at which 
the fluorescence of each sample passes the fixed threshold. T h e � � C t method for 
relative quantitation of gene expression was used to determine miRNA expression 
levels. The Zl ziCt was calculated by subtracting the Ct of U6 RNA from the Ct of 
the miRNA of interest. The � C t was calculated by subtracting t h e � � C t of the 
reference sample (normal liver cell) from the ZM Ct of each sample. Fold change 
was generated using the equation .The Taqman MicroRNA Assays for U6 
RNA (RNU6B, P/N:4373381; Applied Biosystems) was used to normalize the 
relative abundance of miRNA. 
2.10 Lenti-vector Construction for miRNA expression 
For the construction of pniiR-122a, 210 nt encompassing the stem-loop 
pre-miRNA were PGR amplified from MIHA cell genomic DNA using primers 
indicated below.. PGR product was digested with Sal I / EcoR I and inserted 
into pU6 at corresponding sites. The obtained construct was then digested with EcoR 
I / Cla I and cloned into the Lenti-vector plasmid LUNIG at corresponding sites. 
Primers for PGR amplification of miRNA-122a gene: 
Forward : gcg gtcgac ATGGTGGAATGTGGAGGTGAAG 
Reverse : g gaattc aaaaa AGATTGAGAAGACTGATATC 
2.11 Lentivirus production 
Seed and incubate 5 x 10^ 293T cells per 10 cm dish approximately 24 hours 
prior to transfection, in DMEM with 10% FBS. Two hours prior to transfection, 
change media.Prepare plasmid DNA in 50 ml conical tubes as follows: 
Per 10 cm dish: 15 ug transfer vector plasmid 
8 ug MDL-G/P-RRE plasmid 
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4 ug CMV-VSVG plasmid 
6 ug RSV-REV plasmid 
Bring up to a total volume of 450 ul with diluted TE Add 50 ul 2.5M CaC12 and mix 
them thoroughly . Add 500 ul 2 X HBS drop wise，while vortexing at full speed 
(about 2 drops per second). Immediately add total volume to plate of 293T cells and 
swirl plate to disperse precipitate. Incubate plates at 37�C. Change media 
approximately 16 hours later. Collect the media 48 hours later, filter through 0.45 um 
filter and then centrifuge at 9000rpm 4°C for no less than 16h. Pour off supernatant, 
resuspend pellet in a small volume of PBS with IxTBS., aliquot, and store at -80°C. 
Diluted TE: Dilute IXTE 1:15 in sterile water 
IX TE: 0.5 ml IM Tris.HCl, pH 7.5 
0.25 ml 200 mM EDTA 
in 50 ml total. Filter through 0.22um filter 
2.5M CaC12: 18.38 g in 50 ml water. Filter through 0.22 um filter. 
Aliquot and freeze at -20°C 
2X HBS: 8.0gNaCl 
(Note - store 0.37g KCl 
at -20°C. 0.19g Na2HP04.7H20 
Do not store 1.0 g dextrose 
in fridge for 5.0gHEPES 
more than 2 wks) Adjust pH to 7.2, bring volume up to 500 ml. 
Filter through 0.22 um filter. Aliquot and freeze at -20°C. 
2.12 Lentiviral vector titering 
The RRL-CMV-GFP lentiviral vector plasmid which expresses the GFP gene 
under the control of the CMV promoter was serially diluted to establish the standard 
curve by real-time PGR at 103，104,105，106，107，108 copies/ul .lul of lentiviral vector 
supernatant was reverse transcribed into cDNA using ImProm-II™ Reverse 
Transcription System (Promega Cat.#A3800).Real-time PGR was performed on ABI 
7500 Real-Time PGR System .Amplification condition was as follows: one cycle of 
50° C for 2 min, one cycle of 95° C for 10 min, and 45 cycles of 95° C for 15 s 
and 60° C for 2 min 
2.13 Bradford protein assay 
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Prepare protein dye reagent (Bio-rad Catalog #500-0006) by diluting 1 part Dye 
Reagent Concentrate with 4 parts distilled, deionized water. Prepare six dilutions of a 
protein standard BSA(Bovine serum albumin), which is representative of the protein 
solution to be tested. The linear range of the assay for BSA is 0.2 to 0.9 
mg/ml.Usually we add lul, 2ul, 4ul, 6ul, 8ul, lOul BSA (Img/ml) into 1ml diluted 
dye reagent respectively to measure the standard curve.Add lul sample to 1ml 
diluted dye reagent, mix thoroughly and incubate at room temperature for at least 5 
minutes. Measure absorbance at 595 nm. Prepare a graph of Absorbance at 595 nm 
vs [Protein] for the protein standards, To determine the protein concentration of a 
sample from its absorbance, use the standard curve to find the concentration of 
standard that would have the same absorbance as the sample 
2.14 Western Blot 
2.14.1 Sample preparation 
Remove medium from 6-well plate of adherent cells and rinse plate rapidly with 
phosphate-buffered saline (PBS) twice.. Add 1ml PBS to the plate, scrape cells from 
the bottom of wells, transfer to a microcentrifuge tube, centrifuge at 4,000 rpm then 
aspirate excess PBS .Add suitable amount of RIP A lysis buffer .Place the tube on ice 
for 3 Omin,vigorously vortex the tube every lOmin.Centrifuge the sample at 
l,4000rpm for 5 minutes and collect the supernatant, which contains the cell 
lysate.Determine the protein concentration by Bradford protein assay as described 
above. 
RIPA lysis buffer: 
1% sodium deoxycholate 
0.1% SDS 
1% Triton X-100 
1% bovine hemoglobin 
1 mM iodoacetamide 
Protease inhibitors:PMSF 
10 mM Tris.HCl pH 8.0 
140 mM NaCl 
0.025% NaN3 
2.14.2 Gel electrophoresis 
Guidelines for choosing the percent gel to be used for certain molecular weight 
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proteins (based on 37:1 acrylamide: bis acrylamide ratio) 
4-50/0 gels: > 250 kDa 
7.5% gels: 250-120 kDa 
10% gels: 120-40 kDa 
13% gels: 40-15 kDa 
15% gels: <20 kDa 
Add appropriate volume of 5X loading buffer to all samples and boil for 5 
minutes. Apply 10-20 |ig total protein of cell lysate to each well of a 0.75 mm thick 
gel. Electrophorese until the bromophenol blue in the samples reaches the bottom of 
the gel. Turn off power supply. Keep gels in running buffer until ready to transfer. 
5X loading buffer: 
125 mMTris pH 6.8 
40/0 SDS 
10% glycerol 
0.006% bromophenol blue 
1.8% B-mercaptoethanol 
2.14.3 Wet Transfer 
Transfer Buffer: 25 mM Tris, 190 mM glycine, 20% MeOH，pH adjusted to 8.0. 
For transfer of proteins smaller than 120 kDa, transfer proteins from gel to PVDF 
membrane at 1 Amp constant current for 1 hour or equivalent (250 mAmp for 4 
hours or 500 mAmp for 2 hours) in transfer buffer. 
2.14.3 Blocking 
Remove the blot from the transfer apparatus and immediately place into blocking 
buffer (5% non-fat dry milk, 10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20). 
Incubate the blot for 120 minutes at room temperature, or overnight at 4°C. 
2.14.4 Incubation with Primary and Secondary Antibodies 
2.14.4.1 Primary antibody incubation 
Dilute the antibody in the corresponding blocking buffer. Decant the blocking 
buffer from the blot, add the antibody solution, and incubate with agitation for 120 
minutes at room temperature and then overnight at 
2.14.4.2Enzyme conjugated secondary antibody incubation 
Decant the primary antibody solution, add wash buffer (10 mM Tris pH 7.5, 100 
mM NaCl, 0.1% Tween 20), and wash for 30 minutes with agitation, changing the 
wash buffer every 3-5 minutes. Dilute the enzyme conjugate anti-mouse IgGiHRP 
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(Catalog# 554002) 1:3000 in wash buffer containing 5% non-fat dry milk. Decant the 
wash buffer, add the diluted enzyme conjugate and incubate with agitation fori20 
minutes at room temperature. 
2.14.5 Substrate Incubation 
Decant the secondary antibody solution, add wash buffer (10 mM Tris pH 7.5, 
100 mM NaCl, 0.1% Tween 20), and wash for 30 minutes with agitation, changing 
the wash buffer every 3-5 minutes. Decant wash buffer and place the blot in a plastic 
bag containing chemiluminescent working solution (Millipore Immobilon Western 
HRP Substrate Catalog#WBKL SO 100). Rotate the bag to allow the solution to cover 
the surface of the membrane for 1-5 minutes. Remove blot from the bag and place it 
between two pieces of write-on acetate transparency film. Smooth over covered blot 
to remove air bubbles and excess substrate. 
2.14.6 Exposeto x-ray film 
Exposure of 10 Seconds to 5min is appropriate for the Detection Reagents . 
(Millipore Immobilon Western HRP Substrate Catalog#WBKL SO 100) 
2.15 MTT Cell Proliferation Assay 
5X 10^cells/well were plated in triplicates into 96-well plate and propagated in 
complete medium. Cell proliferation was assayed for 6 days continuously at which 
the time point was 24h，48h，72h,96h,120h，144h. At each time point, lOul MTT 
Reagent was added to the well, and then incubated for 4h at 37°C until purple 
precipitate is visible. lOOul DMSO was then added to each well to dissolve the 
precipitate, after 30min of incubation,the absorbance was measured at wavelength 
490nm by Bio-Rad microplate reader. MTT stock solution: 5mg/ml MTT (Sigma) in 
1 X PBS.This solution is filtered through a 0.2 jam filter and stored at 4°C. 
2.16 Apoptosis analysis : DAPI Staining 
Cells were harvested and fixed in 70% ethanol for 24 h at - 2 0 � C . A stock 
solution of DAPI was prepared by dissolving 1 mg of DAPI in 10 ml of ultrapure 
water. Cell suspensions were mixed with the stain at a final concentration 10 ug/ml 
and then incubated for 5 min at room temperature in the dark. After the incubation, 
the stained cells were observed by a fluorescence microscopy. Nuclear chromatin 
condensation and nuclear fragmentation could be observed in potential apoptotic 
nuclei. 
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2.17 2-D Protein Gel Electrophoresis and MS 
2.17.1 Materials 
IPG DryStrip, IPG buffer, Nuclease Mix, Protease Inhibitor Mix, acrylamide, 
bis-acrylamide, DTT, Tris, CHAPS, bromophenol blue, and iodoacetamide were 
purchased from Amersham Biosciences (Piscataway, NJ). TEMED, Ammonium 
persulfate and SDS were from USB Corporation (Cleveland, OH ). Urea, thiourea, 
PMSF, a -cyano-4- hydroxycinnamic acid (CHCA), trifluoroacetic acid (TFA), TBP 
and silver nitrate were products of Sigma (St. Louis, MO). Acetonitrile and trypsin 
(Sequencing Grade) were from Merck (Darmstadt, Germany) and Promega (Madison, 
WI), respectively. Other chemicals were of analytical grade and purchased from 
either Sigma or USB Corporation. 
2.17.2 Protein extraction 
The cell pellets were re-suspended in lysis buffer (8 M urea, 2 M thiourea, 2% 
CHAPS, 1% NP-40，2 mM TBP, IX Protease Inhibitor Mix , 1 X Nuclease Mix , 
ImM PMSF, and 2% IPG buffer). The samples were treated on ice for 45 mins. 
The lysate was then centrifuged at 16000g for 30 min at 4° C and the supernatant 
was saved and stored at -80° C until use. Protein concentration of 2-DE samples was 
measured using a commercial Bradford reagent (Bio-Rad, Hercules, CA). 
2.17.3 2-D Electrophoresis 
lEF was carried out using IPGphor II apparatus (Ammersham). IPG strips (13cm, 
pH4-7) were used according to the manufacturer's introductions. Samples containing 
150 u g protein were diluted to 250 u L in rehydration solution (8M Urea, 2% 
CHAPS, 0.4% DTT, 0.5% IPG buffer, 0.002% bromophenol blue). The rehydration 
step was carried out with 13 cm IPG strips for 10 hours at low voltage of 30V. lEF 
was run following a step-wise voltage increase procedure: 500V and lOOOV for 1 
hour each and 8000 V for 64KVh. After lEF，IPG gel strips were placed in an 
equilibration buffer (6M urea, 2% SDS, 30% glycerol, 0.002% bromophenol blue, 
50mM Tris-HCl, pH6.8) containing 1% DTT for 15min under agitation. The IPG 
strips were then transferred to the equilibration solution containing 2.5% 
iodoacetamide and shaken for a further 15min before submitting them onto 12.5% 
uniform polyacrylamide gel slabs(150X 158 X 1.5mm). Separation in the second 
dimension was performed in Tris-glycine buffer (25 mM Tris, 0.2 M glycine, 0.1% 
SDS) at a constant current setting of 15mA/gel for 30 min and 30 mA/gel thereafter. 
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SDS-PAGE was terminated when the bromophenol dye front had migrated to the 
lower end of the gels. 
2.17.4 Gel staining and image analysis 
After 2-DE, the gels were stained by a modified silver-staining method which is 
compatible with the following MS analysis. The whole staining procedure was 
carried out at room temperature with gels in gentle shaking. Briefly, gels were fixed 
in 50% methanol containing 12% acetic acid and 0.0185% formaldehyde overnight. 
Fixed gels were rinsed three times in water followed by the equilibration in 50% 
ethanol for 2 times. Sensitization was performed by immersing the gels in 0.02% 
sodium thiosulfate for lOmin. After a brief wash in water for 3 times, gels were 
incubated in 0.15% silver nitrate containing 0.0278% formaldehyde for Ih. 
Development was carried out in 3% sodium carbonate containing 0.037% 
formaldehyde until protein spots appeared with a suitable intensity against the 
background. Staining was stopped by transferring the gels to 5% acetic acid and 
incubating for at least lOmin. The raw images were digitalized using a scanner 
(GS-800 calibrated densitometer, Bio-Rad) and Quantity One software (Bio-Rad). 
The images were further analyzed using PDQuest (version 8.0, Bio-Rad). 
2.17.5 In-gel protein digestion with trypsin 
Spots of interest were manually excised from the 2D gels. Gel chips were soaked 
in an equal volume mixture of 30 mM potassium ferricyanide and 100 mM sodium 
thiosulfate for 5 min. After washing twice in water, gel chips were equilibrated in 50 
mM ammonium bicarbonate for 20 min and then in 25 mM ammonium bicarbonate 
and 50% acetonitrile (ACN), followed by being soaked in 100% ACN until gels turn 
opaque white. Vacuum-dried gel chips were rehydrated with 10 u g/mL of trypsin in 
25 mM ammonium bicarbonate, pH 8.0. Proteins were proteolysed for 16-18 h at 37 
° C and the peptide supernatants were spotted onto the target plate with a -cyano-4-
hydroxycinnamic acid as the matrix( 4 mg/mL in 35% ACN and 1% TFA). 
2.17.6 MALDI-TOF MS and database search 
MALDI-TOF MS was performed on a 4700 Proteomics Aanlyzer ( T O F / T O F ™ ) 
(Applied Biosystems, USA) equipped with a 355-nm NdiYAG laser. The instrument 
was operated in the positive ion reflection mode at 20 kV accelerating voltage and 
batch mode acquisition control. Reflector spectra were obtained over a mass of 
850 — 3000 Da. All mass spectra were internally calibrated with ACTH peptide and 
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trypsinized alcohol dehydrogenase peaks. Peptide mass mapping was carried out 
using the program MASCOT (Matrix Science, London, UK) against Swiss-Prot 
database with GPS explorer software (Applied Biosystems, USA). During the 
database searching, a maximum of one missed cleavage per peptide was allowed, a 
mass tolerance of 0.5 Da, and MS/MS tolerance of 0.1 Da was used, and variable 
modifications, such as carbamidomethylation for cysteine and oxidation for 
methionine, were taken into account. Tryptic autolytic fragments and contamination 
were removed from the data set used for database search. 
2.18 Statistical Analysis 
Data are expressed as the mean 土 standard error (SE) from at least 3 separate 
experiments performed in triplicate,unless otherwise noted. 
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Chapter 3 
Expression of HCC-associated miRNA in HCC cell lines 
3.1 Introduction 
MicroRNAs (miRNAs) are a family of 21- to 25-nucleotide,noncoding small 
RNAs that primarily function as gene regulators�The tiny molecules have diverse 
biological functions. They have been implicated in critical processes including 
differentiation, apoptosis, proliferation, and the maintenance of cell and tissue 
identity; furthermore, their misexpression has been linked to cancer and other 
diseases2,3，4. As we know, all types of cancers share a number of characteristics, such 
as the loss of cellular identity, an increased ability to grow and proliferate, and 
alterations in the systems controlling cell death. Studies performed in a variety of 
organisms have revealed the ability of miRNAs to regulate these cellular processes, 
suggesting that they could be involved in cancer^. And the fact that multiple miRNAs 
are aberrantly expressed in human malignancies suggests they may represent a novel 
class of oncogenes or tumor suppressor genes^. 
In our study, we are concerned with the deregulated miRNAs in Hepatocellular 
carcinoma (HCC) which accounts for 80% to 90% of liver cancers and it is one of 
the most prevalent carcinomas throughout the world ranking the third leading cause ！ 
of death from cancer^. Down-regulation of miRNAs was observed in the majority of ‘ 
HCCs and HCC-derived cell lines. The high frequency of aberrant regulation of these 
miRNAs in HCC versus nontumor liver suggests that they might play an important 
role in hepatocarcinogenesis^. In a previous study by Laura Gramantieri et. al using a 
genome-wide miRNA microarray，they identified thirty-five differentially expressed 
miRNAs in HCCs arisen on cirrhotic livers, among which members of the let-7 
family, miR-221, and miR-145 were also found deregulated in other human cancers. 
Notablely, miR-122，a liver specific miRNA was found downregulated in about 70% 
of HCCs . Here in our research,we studied the expression pattern of miR-let7a， 
miR-221 and miR-122 in a series of HCC cells, ie. HepG2, Hep3B, Bel7404 and an 
immortalized liver cell line-MIHA .The miRNA-specific quantitative Real-time PGR 
is the main tool used in this study. 
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3.2 Experimental Section 
3.2.1 Cell culture 
HCC cell lines (MIHA,Hep3B,Bel 7404，HepG2) were cultured with Dulbecco's 
Modified Eagle's Medium supplemented with 10% fetal bovine serum and 100 
units/ml of penicillin G sodium, and lOOg/ml streptomycin sulfate in a humidified 
atmosphere containing 5% CO2 at 37 °C. 
3.2.2 RNA extraction 
Cells cultured in 10cm dish were lysed by adding 1ml TRIzol Reagent and the 
cell lysate were passed through a pipette several times. Incubate the homogenized 
samples for 5 minutes at room temperature to permit the complete dissociation of 
nucleoprotein complexes. Add 0.2 ml of chloroform, cap sample tubes securely and 
shake tubes vigorously by hand for 15 seconds and incubate them at room 
temperature for 2 to 3 minutes. Centrifuge the samples at 14,000 rpm for 15 minutes 
at 4°C .Transfer the aqueous phase to a fresh tube. Precipitate the RNA from the 
aqueous phase by mixing with 0.5ml isopropyl alcohol. Incubate samples at room 
temperature for 10 minutes and centrifuge at 14,000 rpm for 10 minutes at 4 °C. The 
RNA precipitate forms a gel-like pellet on the side and bottom of the tube.Remove 
the supernatant and wash the RNA pellet once with 1ml 75% ethanol. Mix the 
sample by vortexing and centrifuge at 7,500 rpm for 5 minutes at 4 °C. At the end of 
the procedure, briefly air-dry the RNA pellet for about lOmin and dissolve it in lOOul 
DEPC-treated water. 
The amount of RNA was determined by spectrophotmetry and readings were 
taken at 260nm.A 2ul of sample was dissolved into 98ul water. An OD 260 of 1 was 
taken to correspond to approximately 40 ug/ml RNA.The purity of nucleic acids was 
determined by the ratio between the readings at 260 nm and 280nm.Pure preparation 
of RNA has a OD260/OD280 value of around 2.0. 
3.2.3 miRNA-specific quantitative Real-time PGR 
The expression of mature miRNAs was assayed using the Taqman MicroRNA 
Assays (Applied Biosystems) specific for hsa-miR-122a (P/N: 4373151)，hsa-let-7a 
(P/N: 4373169)，and hsa-miR-221 (P/N: 4373077) on an immortalized liver cell and 
a series of HCC cells including HepG2，Hep3B, Bel 7404.Reverse transcription 
reaction was done starting from lug of total RNA and using the looped primers. 
Real-time PCR was done using the standard Taqman MicroRNA Assays protocol on 
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the Applied Biosystems 7500 Real-Time PGR System (ABI). The 20 ul PGR 
included 1.33 ul reverse transcription product, IxTaqman Universal PGR Master Mix, 
No AmpErase UNG (P/N 4324018; Applied Biosystems), 0.2 umol/L Taqman probe, 
1.5 umol/L forward primer, and 0.7 umol/L reverse primer. The reactions were 
incubated at 95 "C for 10 min followed by 40 cycles of 9 5 � C for 15 s and 60 °C 
for 1 min. The level of miRNA expression was measured using Ct (threshold cycle). 
The Ct is the fractional cycle number at which the fluorescence of each sample 
passes the fixed threshold. The A A Ct method for relative quantitation of gene 
expression was used to determine miRNA expression levels. T h e � � C t was 
calculated by subtracting the Ct of U6 RNA from the Ct of the miRNA of interest. 
T h e � C t was calculated by subtracting the zj zl Ct of the reference sample (normal 
liver cell) from the ZM Ct of each sample. Fold change was generated using the 
equation .The Taqman MicroRNA Assays for U6 RNA (RNU6B, 
P/N:4373381; Applied Biosystems) was used to normalize the relative abundance of 
miRNA. Each sample was analyzed in triplicate. 
3.3 Results and Discussion 
3.3.1 Expression of miR-let7a in HCC cells 
Figure 3.1 shows the expression level of miR-let7a in MIHA,Hep3B，Bel 
7404 and HepG2. The expression level in MIHA was taken as 100.We can see that 
compared to the liver cell, the expression of miR-221 is up-regulated in HCC cell 
lines. 
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Figure 3.1 Relative expression level of has-miR-let7a in HCC cell 
lines HepG2,Hep3B,Bel 7404 compared to in MIHA, an 
immortalized liver cell line. The expression level of miR-122a in 
MIHA was taken as 100. Error bars show standard deviation. 
Several studies investigating the role of miRNA deregulation in human 
hepatocarcinogenesis have been reported.However,the results concerning miR-let7a 
seemed to be quite conflicting.lt was shown to be down-regulated in 70% of HCCs 
by Laura Gramantieri et. al using a genome-wide miRNA microarray^. On the 
contrary, in Huban Kutay's study, miR-let7a was found to be up-regulated in both 
Rodent and Human Hepatocellular Carcinomas^. While in the microarray-based 
study by Murakami et al. using a two-color approach,no obvious deregulation of 
miR-let7a has been observed'®. In this study, our data is in agreement with Huban 
Kutay's，that is,miR-let7a is up-regulated in HCC cells compared to the immortalized 
liver cell line. 
3.3.2 Expression ofmiR-221 in HCC cells 
Figure 3.2 shows the expression level ofmiR-221 in MIHA,Hep3B,Bel 7404 and 
HepG2. The expression level in MIHA was taken as 100.We can see that compared 
to the liver cell, the expression of miR-221 is up-regulated in HCC cell lines. 
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Figure 3.2 Relative expression level of has-miR-221 in HCC cell 
lines HepG2, Hep3B, Bel 7404 compared to in MIHA, an 
immortalized liver cell line. The expression level of miR-122a in 
MIHA was taken as 100. Error bars show standard deviation. 
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miR-221 has been previously reproted to be up-regulated in various human 
cancers,ie. thyroid carcinomas,glioblastoma, urinary bladder cancer and pancreatic 
cancerii’i2’ i3，i4 Here in our study, we identified its up-regulation in HCC cells as 
well which supported an oncogenic role for this miRNA in different human 
neoplasms. 
3.3.3 Expression of miR-122a,a liver-specific miRNA in HCC cells 
Figure 3.3 shows the expression level of the liver-specific miRNA miR-122a in 
MIHA,Hep3B,Bel 7404 and HepG2. The expression level in MIHA was taken as 
100.We can see that compared to the liver cell, the expression of miR-122a is 
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Figure 3.3 Relative expression level of has-miR-122a in HCC cell 
lines HepG2,Hep3B , Bel 7404 compared to in MIHA, an 
immortalized liver cell line. The expression level of miR-122a in 
MIHA was taken as 100. Error bars show standard deviation. 
The fact that miR-122a is specifically expressed in normal liver, accounting for 
70% of the total liver miRNA population both in human and mouse suggests its 
important role in liver physiology'^.Hence, it is conceivable that its deregulation may 
have a significant effect on various liver functions.Previous studies have indentified 
miR-122a as an essential element of the HCV (hepatitis C virus) replication 
-adaptation to the liver since it binds to the 5' noncoding region of HCV RNA 
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highly conserved in all HCV genotypes'^ And functional inactivation of miR-122a 
leads to 80% reduction of HCV RNA replication, suggesting that loss of miR-122a in 
HCC may increase resistance of cancer cells to HCV replication..What's more 
related to our study, it has been reported that natural targets of miR-122a include 
several genes related with the adult liver phenotype and genes involved in cholesterol 
biosynthesis suggesting that loss of miR-122a expression in HCC may be related to 
loss of hepatocyte differentiation. Recognizing the down-regulation of miR-122a in 
human HCCs represents the first step for the development of experimental therapies 
of this type. 
3.4 Conclusions 
Several studies investigating the role of miRNA deregulation in human 
hepatocarcinogenesis have been reported 7’9’io Although their data were not so 
consistent with each other possibly due to different approaches,we could still get 
some information and picked up several HCC-associated miRNAs for further 
analysis. The study by Laura Gramantieri et. al identified thirty-five differentially 
expressed miRNAs in HCCs using a genome-wide miRNA microarray^. Among the 
deregulated miRNAs, some were previously found deregulated in other human 
cancers, such as members of the let-7 family, miR-221. Notablely, the liver-specific 
miR-122a was found downregulated in about 70% of HCCs.Here in our study, we 
used the miRNA-specific quantitative Real-time PGR to analyse the expression level 
of the above three miRNAs in a series of HCC cells- HepG2, Hep3B, Bel 7404 and 
in MIHA, an immortalized liver cell line.Our data indentified the down-regulation of 
miR-122a in HCCs and the up-regulation of miR-let7a ,miR-221 in HCCs compared 
to the liver cell.This study helps to define cancer-associated miRNA-deregulated 
pathways involved in liver diseases, which could help to identify potential 
therapeutic targets. 
Among the three analysed miRNAs,we choose miR-122a for our further 
study,since it's specifically expressed in normal liver, accounting for 70% of the total 
liver miRNA population both in human and mouse which suggests its important role 
in liver physiology. Considering its down-regulation in HCCs,we'd like to conduct 
the ectopic overexpression of miR-122a in HCCs for the gain-of-function study. 
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Chapter 4 
Ectopic overexpression of miR- 122a in HCC cells 
4.1 Introduction 
In Huban Kutay's research, the downregulation of miR-122 was found in both 
rodent and human hepatocellular carcinomas. Their study in human primary HCCs 
miR-122 expression was significantly reduced in 10 out of 20 tumors compared to 
the pair-matched control tissues'. Laura Gramantieri et. al reported a comprehensive 
analysis of miRNA expression in HCCs arisen on liver cirrhosis (LC).According to 
their data, thirty-five miRNAs emerged as differentially regulated in HCC tissue 
among wich the hepato-specific miR-122a was strikingly found downregulated in 
about 70% of HCCs^. And our previous study has confirmed the downregulation of 
miR-122 in several HCC cell lines. These findings suggest that the downregulation 
of miR-122 is associated with hepatocarcinogenesis and could be a potential 
biomarker for liver cancers. Based on these, we turned to ectopic overexpression of 
miR-122a in HCC cells for the gain-of-function studies. 
There are several ways for gain-of-function studies. Chemically synthesized 
miRNA presursor molecule which are designed to mimic endogenous mature miRNA 
or "mimics" directely are both able to increase miRNA expression. In addition, stable 
gain-of-function can be achieved by overexpression of individual miRNAs upon 
retro-or lentiviral transfer of suitable miRNA-expression cassettes�’*’�. In our studies, 
we utilized chemically synthesized miRNA mimics which resembled endogenous 
mature miRNA. Meanwhile,we have tried to construct a lentiviral vector with 
miRNA-expression cassettes for stable gain-of-function study since analysis of 
miRNA function requires methods to generate stable gain- and loss-of-function 
phenotypes for individual miRNAs and subsequent identification and isolation of 
modified cells. 
4.2 Experimental Section 
4.2.1 Overexpression of miR-122a with mimics 
4.2.1.1 Cell culture 
Cells were cultured with Dulbecco's Modified Eagle's Medium supplemented 
with 10% fetal bovine serum and 100 units/ml of penicillin G sodium, and lOOg/ml 
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streptomycin sulfate in a humidified atmosphere containing 5% CO2 at 3 7 � C 
4.2.1.2 Cell transfection with miR-122a mimics 
Mature miRNA mimics has-mir-122a (Cat#C-300094-01 -0005) and Mimic 
Negative Control (Cat# CN-001000-01-05) were purchased from DHARMACON. 
Transfection of miRNAs was carried out using Lipofectamine 2000 in accordance 
with the manufacturer's procedure (Invitrogen). The day before transfection, 5x10^ 
cells/well were seeded into 96-well plate containing lOOul medium for each well. For 
each transfection sample, miRNA mimics-Lipofectamine 2000 complexes were 
prepared as follows:dilute lOOnM miRNA mimics in 25ul medium without FBS,mix 
gently. Mix Lipofectamine 2000 gently before use, then dilute 0.5ul in 25ul medium 
without FBS. Mix gently and incubate for 5 minutes at room temperature. After the 
5-minute incubation, combine the diluted mimics with the diluted Lipofectamine 
2000. Mix gently and incubate for 20 minutes at room temperature.Add the 
mimics-Lipofectamine 2000 complexes to each well containing cells and medium. 
Mix gently by rocking the plate back and forth. Incubate the cells at 37°C , change 
medium after 4-6 hours. 
The level of miR-122a expression in transfected HCC cell line was assayed by 
real-time RT-PCR (Taqman MicroRNA Assays) 48 h after transfection. 
4.2.1.3 RNA extraction 
Cells were lysed by adding appropriate amount of TRIzol Reagent and the cell 
lysate were passed through a pipette several times. Incubate the homogenized 
samples for 5 minutes at 15 to 30°C to permit the complete dissociation of 
nucleoprotein complexes. Add 0.2 ml of chloroform per 1 ml of TRIzol Reagent. Cap 
sample tubes securely. Shake tubes vigorously by hand for 15 seconds and incubate 
them at room temperature for 2 to 3 minutes. Centrifuge the samples at 14,000 rpm 
for 15 minutes at 4°C .Transfer the aqueous phase to a fresh tube. Precipitate the 
RNA from the aqueous phase by mixing with isopropyl alcohol. Use 0.5 ml of 
isopropyl alcohol per 1 ml of TRIzol Reagent used for the initial 
homogenization. Incubate samples at at room temperature for 10 minutes and 
centrifuge at 14,000 rpm for 10 minutes at 4 °C. Remove the supernatant. Wash the 
RNA pellet once with 75% ethanol, adding 1 ml of 75% ethanol per 1 ml of TRIzol 
Reagent used for the initial homogenization. Mix the sample by vortexing and 
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centrifuge at 7,500 rpm for 5 minutes at 4 °C. At the end of the procedure, briefly 
air-dry the RNA pellet for about lOmin and dissolve it in appropriate amount of 
DEPC-treated water. 
4.2.1.4 Expression level of miR-122a after transfection 
The expression of mature miRNAs was assayed using the Taqman MicroRNA 
Assays (Applied Biosystems) specific for hsa-mir-122a (P/N: 4373151) on 
transfected cells.Each sample was analyzed in triplicate. Reverse transcription 
reaction was done starting from lug of total RNA and using the looped primers. 
Real-time PGR was done using the standard Taqman MicroRNA Assays protocol on 
the Applied Biosystems 7500 Real-Time PGR System (ABI). The 20 ul PGR 
included 1.33 ul reverse transcription product, 1 xTaqman Universal PGR Master Mix, 
No AmpErase UNG (P/N 4324018; Applied Biosystems), 0.2 umol/L Taqman probe, 
1.5 umol/L forward primer, and 0.7 umol/L reverse primer. The reactions were 
incubated at 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 V 
for 1 min. The level of miRNA expression was measured using Ct (threshold cycle). 
The Ct is the fractional cycle number at which the fluorescence of each sample 
passes the fixed threshold. T h e � � C t method for relative quantitation of gene 
expression was used to determine miRNA expression levels. T h e � � C t was 
calculated by subtracting the Ct of U6 RNA from the Ct of the miRNA of interest. 
T h e � � C t was calculated by subtracting t h e � � C t of the reference sample (normal 
liver cell) from the Zl ACt of each sample. Fold change was generated using the 
equation 2 . � � ^ j h e Taqman MicroRNA Assays for U6 RNA (RNU6B, 
P/N:4373381; Applied Biosystems) was used to normalize the relative abundance of 
miRNA. 
4.2.2 Lentivirus-mediated miR-122a expression 
4.2.2.1 Cell culture 
Culture conditions were the same as described in 4.2.1.1 
4.2.2.2 Genomic DNA extranction from MIHA cell 
Wash the cell with IxPBS and harvest the cells from 10cm dish by 
trypsinization.Resuspend the cell in 400ul of lysis buffer (50mM Tris-Cl pH 8.0， 
0.5% SDS lOmM EDTA).Add 4ml of proteinase K(20mg/ml) to sample (final 
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concentration 200ug/ml) ,mix and incubate at 55 °C for 2h.Add 0.8ul of RNase 
A(10mg/ml) to sample (final concentration 20ug/ml) mix and incubate at 37°C for 
lh,add NaCl to final concentration of 0.2M. Extract twice with phenol: 
chloroform(l:l) (200ul:200ul) and once with chloroform (400ul). Add 1ml of EtOH 
and 0.1 volume of 3M NaAcetate (PH 5.0), incubate at -20°C for 3Omin.Centrifuge 
for 10 min.Add 1ml of 70% EtOH to wash the pellet. Dry the pellet and resuspend 
the pellet in TE or dH20,heating at 65 °C for 10 min. Measure the concentration 
A260/A280 ratio should be 1.9 (not over 2.0 or under 1.8 ) and run gel to check. 
4.2.2.3 Construction of lentiviral vector expressing miR-122a 
We cloned human U6 promoter from pU6B by PCR. [22. Chen Y， 
Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small 
interfering RNA inhibits breast cancer cell invasion in vitro, Cancer Res 
2003;63:4801-4804.] The forward primer contained Xhol and Clal sites (5，-GCG 
CTCGAGATCGATAAGGTCGGGCAGGAAGAGGG-3，)，whereas the reverse 
primer contained a Sail site immediately downstream of the transcription initiation 
site for the U6 promoter and an EcoRI site at the 5' end (5'-GGAATTCAAAAA 
GTCGACGGTGTTTTCGTCCTTTCCAC-3，).We cloned the amplified U6 promoter 
into the Xhol and EcoRI site of the pBluescript II KS(+) to generate pU6. For the 
construction of pmiR-122a, 210 nt encompassing the stem-loop pre-miRNA were 
PCR amplified from MIHA cell genomic DNA using primers indicated below 
(Figure 4.1). The target sequence was amplified by PCR under 94°C for 5 min; 94 °C 
for 30 s, 55°C for 30 s, 72"C for 30 s，30 cycles. PCR product was recycled and 
purified (QIAquick Gel Extraction Kit) then digested with Sail/ EcoRI and inserted 
into pU6 at corresponding sites. The correct sequence and insertion was confirmed 
by DNA sequencing (Tech Dragon Limited).The obtained construct was then 
digested with Clal/ EcoRI and cloned into the Lentiviral vector plasmid LUNIG at 
corresponding sites.All lentiviral constructs encode EGFP as reporter gene. 
Generation of the lentiviral vector LUNIG was based on the published 
pRRL-cPPT-CMV-X-PRE-SIN vector (kindly provided by Dr.Osborne's laboratory 
at the University of Washington, Seattle)^. We inserted a Smal/Xbal fragment 
containing the Neores gene from pIRESneo3 (Clontech) into EcoRV/Nhel sites of 
pIRESneo3 vector to generate pNIN. We inserted a Sall/StuI fragment from pNIN 
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and a Smal/Xbal fragment from pIRES2-enhanced green fluorescent protein (EGFP) 
into Xhol/Nhel sites of pRRL-cPPT-CMV-X-PRE-SIN to generate a LUNIG vector?. 
The miR-122a stemp-loop sequence,mature sequence and miR-122a gene 
sequence were listed in Table 4.1. And Figure 4.1 shows the schematic diagram of 







Gene sequence CCTTAGCAGAGCTGTGGAGTGTGACAATGGTGTTTGTGTCTAA 
ACTATCAAACGCCATTATCACACTAAATAGCTACTGCTAGGC 
Table 4.1 miR-122a stemp-loop sequence,mature sequence and miR-122a gene 
sequence. 
Template MIHA genomic DNA 
Primer ——Forward : gcg gtcgac ATGGTGGAATGTGGAGGTGAAG 
Reverse : g gaattc aaaaa AGATTGAGAAGACTGATATC 
Cloning: 
Insert Vector 
PGR product pU6 
cut with Sal 11 EcoR I cut with Sal 11 EcoR I 
I I 
1 ligation 
Insert U6-mir122a Vector LUNIG 
cut with EcoR I / Cla I cut with EcoR I / Cla I 
I r 1 
Xligation 
LUNIG-mir-122a 
Figure 4.1 Schematic diagram of the lentiviral vector cloning process. 
4.2.2.4 Lentivirus production 
Seed and incubate 5 x 10^ 293T cells per 10 cm dish approximately 24 hours 
prior to transfection, in DMEM with 10% FBS. Two hours prior to transfection, 
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change media.Prepare plasmid DNA in 50 ml conical tubes as follows: 
Per 10 cm dish: 15 ug transfer vector plasmid 
8 ug MDL-G/P-RRE plasmid 
4 ug CMV-VSVG plasmid 
6 ug RSV-REV plasmid 
Bring up to a total volume of 450 ul with diluted TE Add 50 ul 2.5M CaC12 and mix 
them thoroughly . Add 500 ul 2 X HBS dropwise, while vortexing at full speed 
(about 2 drops per second). Immediately add total volume to plate of 293T cells and 
swirl plate to disperse precipitate. Incubate plates at 37°C. Change media 
approximately 16 hours later. Collect the media 48 hours later, filter through 0.45 um 
filter and then centrifuge at 9000rpm 4°C for no less than 16h. Pour off supernatant, 
resuspend pellet in a small volume of PBS with 1 xTBS., aliquot, and store at -80°C. 
Diluted TE: Dilute IX TE 1:15 in sterile water 
IX TE: 0.5 ml IM Tris.HCl, pH 7.5 
0.25 ml 200 mM EDTA 
in 50 ml total. Filter through 0.22um filter 
2.5M CaC12: 18.38 g in 50 ml water. Filter through 0.22 um filter. 
Aliquot and freeze at 一 2 0 � C 
2XHBS: S.OgNaCl 
(Note - store 0.37g KCl 
at - 2 0 � C . 0.19g Na2HP04.7H20 
Do not store 1.0 g dextrose 
in fridge for S.OgHEPES 
more than 2 wks) Adjust pH to 7.2, bring volume up to 500 ml. 
Filter through 0.22 um filter. Aliquot and freeze at -20°C. 
4.2.2.5 Lentiviral vector titering 
The RRL-CMV-GFP lentiviral vector plasmid which expresses the GFP gene 
under the control of the CMV promoter was serially diluted to establish the standard 
curve by real-time PGR at 103’104，105,106,107 copies/ul .lul of lentiviral vector 
supernatant was reverse transcribed into cDNA using ImProm-II™ Reverse 
Transcription System (Promega Cat.#A3 800).Real-time PGR was performed on ABI 
7500 Real-Time PGR System .Amplification condition was as follows: one cycle of 
50�C for 2 min, one cycle of 95�C for 10 min, and 45 cycles of 95�C for 15 s and 
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6 0 � C for 2 min 
4.2.2.6 Lentiviral vector transduction 
3x104 cells per well were seeded into 6-well plate 24 hours prior to 
transduction.Before transduction, replace the culture medium with 500ul fresh one 
and add cross linker polybrene directly to the medium at a final concentration of 
8ug/ml,incubate at 37°C for Smin.Dilute lOOul lentiviral vector with lOOul culture 
medium,add polybrene at a final concentration of 8ug/ml,incubate for 5min at room 
temperature.After incubation,add virus and linkers to each well, gently rock the plate 
to ensure even distribution of the vector. 
4.2.3 RNA extraction 
Total RNA was extracted using TRIzol Reagent as described in 4.2.1.3 
4.2.4 Expression level of miR-122a after transduction 
The expression of mature miRNAs was assayed using the Taqman MicroRNA 
Assays (Applied Biosystems) specific for hsa-miR-122a (P/N: 4373151) as described 
in 4.2.1.4. 
4.2.5 Western Blot 
4.2.5.1 Sample preparation 
Remove medium from 6-well plate of adherent cells and rinse plate rapidly with 
phosphate-buffered saline (PBS) twice.. Add 1ml PBS to the plate, scrape cells from 
the bottom of wells, transfer to a microcentrifuge tube, centrifuge at 4,000 rpm then 
aspirate excess PBS .Add suitable amount of RIPA lysis buffer .Place the tube on ice 
for 30min,vigorously vortex the tube every 1 Omin.Centrifuge the sample at 
l,4000rpm for 5 minutes and collect the supernatant, which contains the cell 
lysate.Determine the protein concentration by Bradford protein assay as described in 
2.13. 
4.2.5.2 Gel electrophoresis 
Since the molecular weight of our target protein are around 40kDa,we choose 
12% gel for electrophoresis.Add appropriate volume of 5X loading buffer to all 
samples and boil for 5 minutes. Apply 10-20 |j.g total protein of cell lysate to each 
well of a 0.75 mm thick gel. Electrophorese until the bromophenol blue in the 
samples reaches the bottom of the gel. Turn off power supply. Keep gels in running 
buffer until ready to transfer. 
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4.2.5.3 Wet Transfer 
Transfer Buffer: 25 mM Tris，190 mM glycine, 20% MeOH，pH adjusted to 8.0. 
For transfer of proteins smaller than 120 kDa, transfer proteins from gel to PVDF 
membrane at 1 Amp constant current for 1 hour or equivalent (250 mAmp for 4 
hours or 500 mAmp for 2 hours) in transfer buffer. 
4.2.5.4 Blocking 
Remove the blot from the transfer apparatus and immediately place into blocking 
buffer (5% non-fat dry milk, 10 mM Tris pH 7.5，100 mM NaCl, 0.1% Tween 20). 
Incubate the blot for 120 minutes at room temperature, or overnight at 4°C. 
4.2.5.5 Incubation with Primary and Secondary Antibodies 
4.2.5.5.1 Primary antibody icubation 
Dilute the antibody Cyclin G1 (clone 1 lC8,ThermoScientific) 1:800 in the 
corresponding blocking buffer. Decant the blocking buffer from the blot, add the 
antibody solution, and incubate with agitation for 120 minutes at room temperature 
and then overnight at 4°C 
4.2.5.5.2 Enzyme conjugated secondary antibody incubation 
Decant the primary antibody solution, add wash buffer (10 mM Tris pH 7.5，100 
mM NaCl, 0.1% Tween 20), and wash for 30 minutes with agitation, changing the 
wash buffer every 3-5 minutes. Dilute the enzyme conjugate anti-mouse IgGiHRP 
(Catalog# 554002) 1:1000 in wash buffer containing 5% non-fat dry milk. Decant the 
wash buffer, add the diluted enzyme conjugate and incubate with agitation for 120 
minutes at room temperature. 
4.2.5.6 Substrate Incubation 
Decant the secondary antibody solution, add wash buffer (10 mM Tris pH 7.5, 100 
mM NaCl, 0.1% Tween 20), and wash for 30 minutes with agitation, changing the 
wash buffer every 3-5 minutes. Decant wash buffer and place the blot in a plastic bag 
containing chemiluminescent working solution (Millipore Immobilon Western HRP 
Substrate Catalog#WBKL SO 100). Rotate the bag to allow the solution to cover the 
surface of the membrane for 1-5 minutes. Remove blot from the bag and place it 
between two pieces of write-on acetate transparency film. Smooth over covered blot 
to remove air bubbles and excess substrate. 
4.2.5.7 Exposeto x-ray film. 
Exposure of 10 Seconds to 5min is appropriate for the Detection Reagents • 
(Millipore Immobilon Western HRP Substrate Catalog#WBKL SO 100) 
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4.3 Result and discussion 
4.3.1 Expression level of miR-122a after transfection 
The chemically synthesized miRNA mimics has-miR-122a and mimic control 
(DHARMACON) were transfected into HepG2 cells by Lipofectamine 2000 
(Invitrogen) at the concentration of 1 OOnM.Total RNA was extracted for analysis 48h 
after transfection.The expression of mature miRNAs was assayed using the Taqman 
MicroRNA Assays (Applied Biosystems) specific for hsa-miR-122a.The z l � C t 
method for relative quantitation of gene expression was used to determine miRNA 
expression levels(As described in 4.2.1.4). Fold change was generated using the 
equation 幻 . F i g u r e 4.2 shows the relative expression level of miR-122a in 
HepG2 cells after transfection. 
Relative expression level of niiR-122a 
6000000 
5000000 - T 
4000000 - • • 
3000000 ^ H 
2000000 ^ H 
1000000 ^ H 
0 ‘ ‘ — — ^ — — ‘ 
Blank Ctrl niiR-122a 
transfected 
Figure 4.2 Relative expression level of miR-122a in HepG2 cells 
after transfection with chemically synthesized has-miR 
-122a .Blank corresponds to the cells with no treatment,Ctrl 
corresponds to the cells transfected with mimics negative control and 
the last column corresponds to the cells transfected with miR-122a 
mimics.Expression level in the untreated cells was taken as 100. 
From the figure above,we can see that the mimics have been effectively 
transfected into target cells.This suggests the chemically synthesized miRNA mimics 
may present an useful tool for the gain-of-function study. 
4.3.2 Lentivirus-mediated miR-122a expression 
4.3.2.1 Construction of lentiviral vector expressing miR-122a 
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Our lentiviral vector expressing miR-122a was based on the published pRRL-
cPPT-CMV-X-PRE-SIN vector, Figure 4.3 A shows the schematic diagram of 
Lenti-miRNA vector LUNIG. Since the expression level of miR-122a is relatively 
higher in the MIHA cells,we amplified the desired fragment encompassing the 
stem-loop pre-miRNA of miR-122a from MIHA cell genomic DNA by PGR using 
primers indicated in Figure 4.1.The PGR band of around 210bp in size was obtained 
(Figure4.3 A). PGR product was recycled and purified (QIAquick Gel Extraction 
Kit)and then digested with Sail/ EcoRI and inserted into pU6 at corresponding sites. 
The obtained clonics were PGR screened (Figure 4.3 B) and the positive ones were 
selected for further enzyme digestion confirmation. Figure 4.3 C shows Sail/ EcoRI 
digestion of U6-miR-122a plasmids which were positive in PGR screening.We can 
see that, positive clonics identified in PGR screening may not be the real ones,false 
positive ones can be ruled out in this enzyme digestion step. The correct sequence 
and insertion was finally confirmed by DNA sequencing (Tech Dragon Limited).The 
obtained construct was then digested with Clal/ EcoRI (Figure 4.3 D)and cloned into 
the Lentiviral vector plasmid LUNIG at corresponding sites(Figure 4.3 E). All 
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Figure 4.3 The construction of lentiviral vector expressing miR-122a.(A) 
Schematic diagram of Lenti-miRNA vector pLUNIG, in which miRNA was driven 
by a U6 promoter, and Neores and EGFP were biocistronically expressed under the 
control of a CMV promoter.(B) The PGR amplication of target sequence 
encompassing the stem-loop pre-miRNA of miR-122a from MIHA cell genomic 
DNA. The target fragment was amplified under 94°C for 5 min; 94°C for 30 s，55°C 
for 30 s, 12V for 30 s，30 cycles.MilOObp marker 1-6: pre-mir-122a (C) PGR 
screening of obtained U6-mir-122a clonies.M:100bp marker 1-10: PGR product of 
U6-mir-122a clonics. (D) Sail/ EcoRI digestion of U6-mir-122a after the insertion of 
the PGR fragment. M:lkb marker 1:U6 control 2,4,5: Recombinant plasmid 
U6-mir-122a 3: False positive recombinant plasmid. (E) Enzyme digestion of 
U6-122a with Clal/ EcoRI. M:100bp marker 1-3: Recombinant plasmid U6-mir-122a 
confirmed in (D) .The 500bp fragments were recycled and cloned into the Lentiviral 
vector plasmid LUNIG at corresponding sites (F) Enzyme digestion of 
LUNIG-mir-122a with Clal/ EcoRI. MilOObp marker. 1-6: Recombinant plasmid 
LUNIG-mir-122a 7: LUNIG control. 
4.3.2.2 Lentiviral vector production and titering 
Our lentiviral vector expressing miR-122a was based on the published pRRL-
cPPT-CMV-X-PRE-SIN vector as described in 4.2.2.4. To characterize lentiviral 
vector supernatants, we did the titering assessment. The RRL-CMV-GFP lentiviral 
vector plasmid SL7 which expresses the GFP gene under the control of the CMV 
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promoter was serially diluted to establish the standard curve by real-time PCR at 
103，104，105,106,107 copies/ul (Figure 4.4) According to the standard curve, the titer of 
our lentiviral vector can be calculated. Titers are represented as the copies of vector 
molecules/ul vector supernatant. The titer of our samples,LUNIG-mir-122a and the 
control vector LUNIG-Luc were and 6.88 X 10^ and 4.04 X 10^ copies/ul respectively. 
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Figure 4.4 Amplification plot of the standard lentiviral vector plasmid SL7 
at 103，104，10�106，107 copies/ul. 
4.3.2.3 Overexpression of miR-122a after Lentiviral vector LUNIG-mir-122a 
transduction 
Since our lentiviral constructs encode EGFP as reporter gene, this allows for 
convenient monitoring of the infection efficiency under a fluorescent microscope. 
Figure 4.5 shows the Phase contrast and Fluorescence microscopic images of HepG2 
cells transducted with LUNIG-mir-122a and the control vector LUNIG-Luc 
respectively. By comparing the images,we can tell the lentiviral vectors have been 
effectively transducted into the target cells of which the efficiency is over 90%. 
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• • 
Control vector LUNIG-mir-122a 
Figure 4.5 Efficient transduction of lentiviral vectors in HepG2. Upper pictures 
show phase-contrast images of HepG2 cells. Lower pictures show fluorescence images 
of reporter gene GFP expression in lentiviral vectors. Pictures were taken at 
1 OOxmagnification after 72h of transduction. 
The images above indicate the efficient transduction of lentiviral vectors carrying 
miRNA expression cassettes.Since the biogenesis of mature miRNA is a stepwise 
maturation process,efficient transduction of the vector did not necessarily mean 
efficient expression of the target miRNAs. The expression level of mature miR-122a 
was assayed using the Taqman MicroRNA Assays (Applied Biosystems) as described 
in 4.2.1.4. Figure 4.6 shows the relative expression level of miR-122a 48h after 
transduction with lentiviral vector. We can see our LUNIG-mir-122a vecor works 
efficiently directing intracellular synthesis of mature miRNA which will greatly 
facilitate the gain-of-function study of this liver specific miRNA. 
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Figure 4.6 The expression level of miR-122a in HepG2 after 
transduction.HepG2, HepG2 LUNIG-luc, HepG2 LUNIG-122a 
correspond to cells with no treatment,cells transducted with control 
vector LUNIG-luc and cells transducted with miRNA expressing 
vector LUNIG-122a respectively. The expression level of miR-122a 
in HepG2 with no treatment was taken as 100. Error bars show 
standard deviation. 
4.3.2.4 The expression of Cyclin Gl,a validated target of miR-122a after Lentiviral 
vector LUNIG-mir-122a transduction 
It's reported that miR-122a can modulate cyclin G1 expression in HCC-derived 
cell lines and there's an inverse correlation between miR-122a and cyclin G1 
expression in primary liver carcinomas^. In their research,the human HCC cell line 
HEP3B was chosen for the assay because miR-122a basal expression is undetectable 
and cyclin G1 protein is easily detectable in the cell line.To make sure that our 
lentiviral vector worked,we transducted LUNIG-mir-122a into HEP3B cell, and see 
its effect on the expression of CyclinGl protein.Figure 4.7 shows the western blot 
results,we can see that the expression of Cyclin G1 protein decreased after the 
transduction of the lentiviral vector LUNIG-mir-122a which was consistent with the 
result obtained in previous study^.This confirmed that our lentiviral vector worked 
well in expressing mature miRNA which could be served as a useful tool in 
gain-of-function study. 
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Figure 4.7 Inverse correlation between cyclin G1 and miR-122a expression 
in Hep3B cell by Western blot. 
4.4 Conclusions 
In this chapter,we described two methods for the overexpression of miR-122a 
in HCC cells: the chemically synthesized mimics which resemble endogenous 
mature miRNA and the lentiviral vector with miRNA-expression cassettes.Both of 
the two methods worked well in the overexpression of specific mature miRNA. Since 
analysis of miRNA function requires methods to generate stable gain-and 
loss-of-function phenotypes for individual miRNAs, the construction of a lentiviral 
vector had obvious advantages which also facilitated subsequent identification and 
isolation of modified cells.Our miRNA expression vector was based on an RNAi 
expression system in which the expression of shRNAs is driven by a U6 promoter. 
The lentiviral RNAi expression system offers several advantages over other viral 
vectors^. It can easily infect over 90% of cultured cells, which is sufficient for 
studying the effect of RNAi on endogenous gene expression without having to 
establish stable cell lines. Lentivirus is relatively easy to generate, and thus, has been 
applied for large-scale, highthroughput RNAi assay for studying gene 
functions^.Finally, the safety of using the lentiviral vector in preclinical research is a 
minimal concern, as lentiviral vector encoding antisense targeting HIV envelope 
sequence has been used for HIV treatment in clinical trials with no obvious side 
effectsio'ii.Due to the great advantages of this system, we explored the possibility of 
synthesizing miRNAs in HCC cells based on the RNAi expression vector.In our 
study, we constructed a convenient Lenti-miRNA system in which miRNAs were 
expressed by a U6 promoter, whereas the neomycin resistance gene and EGFP were 
bicistronically expressed by a CMV promoter. The expression of EGFP allowed for 
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convenient monitoring of the infection efficiency under a fluorescent 
microscope.Successful construction of this vector provided us with an efficient and 
inexpensive way for introduction of the miRNAs into cultured cells which may 
facilitate the gain-of-function study for certain miRNAs. 
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Chapter 5 
Gain-of-f unction study of miR_122a in HCC cells 
5.1 Introduction 
In recent years,emerging data have indicated that dysregulation of miRNAs is a 
frequent occurrence in diverse types of cancer. Since more than half of miRNAs are 
located at sites in the human genome that are frequently amplified, deleted, or 
rearranged in cancer,this is a suggestion that miRNA abnormalities may play a broad 
role in cancer pathogenesis ^ Consistent with this notion,studies performed in a 
variety of organisms have revealed the ability of miRNAs in regulating cellular 
processes including the loss of cellular identity, an increased ability to grow and 
proliferate, and alterations in the systems controlling cell death which suggest that 
they could be involved in cancer^. 
Several studies have shown the influence of miRNAs in tumorigenesis by acting 
as oncogenes and tumour suppressors^'^^'^miRNAs with proproliferative and 
antiapoptotic activity would likely promote oncogenesis and thus may be 
overexpressed in cancer cells.On the contrary, miRNAs with antiproliferative and 
proapoptotic activity are likely to function as tumour suppressor genes and thus may 
be underexpressed in cancer cells^ which is the case with our study.Down-regulation 
of miR-122a was observed in the majority of HCCs and HCC-derived cell lines . The 
high frequency of aberrant regulation of this miRNA in HCC versus nontumor liver 
suggests that it might play an important role in hepatocarcinogenesis^'^'^.Here we 
used the constructed lentiviral vector with miR-122a-expression cassettes for stable 
gain-of-function study. We transducted the vector into HCC cells to see whether it 
can cause any phenotypic changes to the cells. 
The accurate prediction and validation of genes targeted by miRNAs is currently 
a major challenge in miRNA biology. An increasing number of sophisticated 
bioinformatics approaches are being utilized to predict putative miRNA target 
genes.And various computational algorithms have been developed for the purpose, 
among which miRanda(http://microrna.sanger.ac.uk)'®, TargetScan (http:// www. 
targetscan.org)ii’i2 ,and PicTar (http://pictar.bio.nyu-edu)'^''"^ are suggested to have 
higher performance v a l u e s H e r e in our study, we used Target Scan and Pic Tar 
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simultaneously for the target prediction. To identify the genes commonly predicted 
by the two different algorithms,results were intersected using MatchMiner'Since 
target prediction by bioinformatic approach tends to cause a relatively higher level of 
both false-positive and false-negative results,we further turned to two-dimensional 
gel electrophoresis, the leading tool in proteomics research, for experimental 
validation of predicted miRNA targets. The changes at protein level were compared 
between HepG2 cells transducted with control lentiviral vector LUNIG-Luc and cells 
transducted with the miR-122a expressing vector. 
5.2 Experimental Section 
5.2.1 Cell culture. 
HCC cell lines were cultured with Dulbecco's Modified Eagle's Medium 
supplemented with 10% fetal bovine serum and 100 units/ml of penicillin G sodium, 
and 1 OOg/ml streptomycin sulfate in a humidified atmosphere containing 5% CO2 at 
37 "C. 
5.2.2 Cell transfection 
Mature miRNA mimics has-mir-122a (CatttC-3 00094-01-0005) and Mimic 
Negative Control (Cat# CN-001000-01-05) were purchased from DHARMACON. 
The day before transfection, HCC cells were seeded in antibioticfree medium. 
Transfection of miRNAs was carried out using Lipofectamine 2000 in accordance 
with the manufacturer's procedure (Invitrogen). 
5.2.3 Lentiviral vector transduction 
3x104 cells per well were seeded into 6-well plate 24 hours prior to 
transduction.Before transduction, replace the culture medium with 500ul fresh one 
and add cross linker polybrene directly to the medium at a final concentration of 
8ug/ml,incubate at 37°C for 5min.Dilute lOOul lentiviral vector with lOOul culture 
medium,add polybrene at a final concentration of 8ug/ml,incubate for 5min at room 
temperature. After incubation,add virus and linkers to each well, gently rock the plate 
to ensure even distribution of the vector. 
5.2.4 MTT Cell Proliferation Assay 
5x10^ cells/well were plated in triplicates into 96-well plate and propagated in 
complete medium. Cell proliferation was assayed for 6 days continuously at which 
the time point was 24h,48h，72h，96h，120h，144h. At each time point, lOul MTT 
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Reagent was added to the well, and then incubated for 4h at 37"C until purple 
precipitate is visible. lOOul DMSO was then added to each well to dissolve the 
precipitate, after 30min of incubation,the absorbance was measured at wavelength 
490nm by Bio-Rad microplate reader. MTT stock solution: 5mg/ml MTT (Sigma) in 
1XPBS.This solution is filtered through a 0.2 m filter and stored at 4�C. 
5.2.5 Apoptosis analysis - DAPI Staining 
Cells were harvested and fixed in 70% ethanol for 24 h at — 20°C . A stock 
solution of DAPI was prepared by dissolving 1 mg of DAPI in 10 ml of ultrapure 
water. Cell suspensions were mixed with the stain at a final concentration 10 ug/ml 
and then incubated for 5 min at room temperature in the dark. After the incubation, 
the stained cells were observed by a fluorescence microscopy. Nuclear chromatin 
condensation and nuclear fragmentation could be observed in potential apoptotic 
nuclei. 
5.2.6 2-D Protein Gel Electrophoresis and MS 
5.2.6.1 Materials 
IPG DryStrip, IPG buffer, Nuclease Mix, Protease Inhibitor Mix, acrylamide, 
bis-acrylamide, DTT, Tris, CHAPS, bromophenol blue, and iodoacetamide were 
purchased from Amersham Biosciences (Piscataway, NJ). TEMED, Ammonium 
persulfate and SDS were from USB Corporation (Cleveland, OH ). Urea, thiourea, 
PMSF, a -cyano-4- hydroxycinnamic acid (CHCA), trifluoroacetic acid (TFA), TBP 
and silver nitrate were products of Sigma (St. Louis, MO). Acetonitrile and trypsin 
(Sequencing Grade) were from Merck (Darmstadt, Germany) and Promega (Madison, 
WI), respectively. Other chemicals were of analytical grade and purchased from 
either Sigma or USB Corporation. 
5.2.6.2 Protein extraction 
The cell pellets were re-suspended in lysis buffer (8 M urea, 2 M thiourea, 2% 
CHAPS, 1% NP-40, 2 mM TBP, IX Protease Inhibitor Mix , 1 X Nuclease Mix， 
ImM PMSF, and 2% IPG buffer). The samples were treated on ice for 45 mins. 
The lysate was then centrifuged at 16000g for 30 min at 4° C and the supernatant 
was saved and stored at -80° C until use. Protein concentration of 2-DE samples was 
measured using a commercial Bradford reagent (Bio-Rad, Hercules, CA). 
5.2.6.3 2-D Electrophoresis 
lEF was carried out using IPGphor II apparatus (Ammersham). IPG strips (13cm， 
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pH4-7) were used according to the manufacturer's introductions. Samples containing 
150 u g protein were diluted to 250 u L in rehydration solution (8M Urea, 2% 
CHAPS, 0.4% DTT，0.5% IPG buffer, 0.002% bromophenol blue). The rehydration 
step was carried out with 13cm IPG strips for 10 hours at low voltage of 30V. lEF 
was run following a step-wise voltage increase procedure: 500V and lOOOV for 1 
hour each and 8000 V for 64KVh. After lEF, IPG gel strips were placed in an 
equilibration buffer (6M urea, 2% SDS, 30% glycerol, 0.002% bromophenol blue, 
50mM Tris-HCl, pH6.8) containing 1% DTT for 15min under agitation. The IPG 
strips were then transferred to the equilibration solution containing 2.5% 
iodoacetamide and shaken for a further 15min before submitting them onto 12.5% 
uniform polyacrylamide gel slabs(150X 158 X 1.5mm). Separation in the second 
dimension was performed in Tris-glycine buffer (25 mM Tris, 0.2 M glycine, 0.1% 
SDS) at a constant current setting of 15mA/gel for 30 min and 30 mA/gel thereafter. 
SDS-PAGE was terminated when the bromophenol dye front had migrated to the 
lower end of the gels. 
5.2.6.4 Gel staining and image analysis 
After 2-DE, the gels were stained by a modified silver-staining method which is 
compatible with the following MS analysis. The whole staining procedure was 
carried out at room temperature with gels in gentle shaking. Briefly, gels were fixed 
in 50% methanol containing 12% acetic acid and 0.0185% formaldehyde overnight. 
Fixed gels were rinsed three times in water followed by the equilibration in 50% 
ethanol for 2 times. Sensitization was performed by immersing the gels in 0.02% 
sodium thiosulfate for lOmin. After a brief wash in water for 3 times, gels were 
incubated in 0.15% silver nitrate containing 0.0278% formaldehyde for Ih. 
Development was carried out in 3% sodium carbonate containing 0.037% 
formaldehyde until protein spots appeared with a suitable intensity against the 
background. Staining was stopped by transferring the gels to 5% acetic acid and 
incubating for at least lOmin. The raw images were digitalized using a scanner 
(GS-800 calibrated densitometer, Bio-Rad) and Quantity One software (Bio-Rad). 
The images were further analyzed using PDQuest (version 8.0, Bio-Rad). 
5.2.6.5 In-gel protein digestion with trypsin 
Spots of interest were manually excised from the 2D gels. Gel chips were soaked 
in an equal volume mixture of 30 mM potassium ferricyanide and 100 mM sodium 
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thiosulfate for 5 min. After washing twice in water, gel chips were equilibrated in 50 
mM ammonium bicarbonate for 20 min and then in 25 mM ammonium bicarbonate 
and 50% acetonitrile (ACN), followed by being soaked in 100% ACN until gels turn 
opaque white. Vacuum-dried gel chips were rehydrated with 10 u g/mL of trypsin in 
25 mM ammonium bicarbonate, pH 8.0. Proteins were proteolysed for 16-18 h at 37 
° C and the peptide supernatants were spotted onto the target plate with a -cyano-4-
hydroxycinnamic acid as the matrix( 4 mg/mL in 35% ACN and 1% TFA). 
5.2.6.6 MALDI-TOF MS and database search 
MALDI-TOF MS was performed on a 4700 Proteomics Aanlyzer (TOF/TOF™) 
(Applied Biosystems, USA) equipped with a 355-nm Nd:YAG laser. The instrument 
was operated in the positive ion reflection mode at 20 kV accelerating voltage and 
batch mode acquisition control. Reflector spectra were obtained over a mass of 
850一3000 Da. All mass spectra were internally calibrated with ACTH peptide and 
trypsinized alcohol dehydrogenase peaks. Peptide mass mapping was carried out 
using the program MASCOT (Matrix Science, London, UK) against Swiss-Prot 
database with GPS explorer software (Applied Biosystems, USA). During the 
database searching, a maximum of one missed cleavage per peptide was allowed, a 
mass tolerance of 0.5 Da, and MS/MS tolerance of 0.1 Da was used, and variable 
modifications, such as carbamidomethylation for cysteine and oxidation for 
methionine, were taken into account. Tryptic autolytic fragments and contamination 
were removed from the data set used for database search. 
5.2.7 miRNA target prediction using bioinformatic approaches 
The analysis of miRNA predicted targets was determined using the algorithms 
TargetScanii’i2’i7,picTari8’i3.To identify the genes commonly predicted by the two 
different algorithms, results of predicted targets were intersected using 
MatchMineri9’i6. 
5.3 Result and discussion 
5.3.1 Phenotypic changes of HepG2 cells caused by ectopic overexpression of 
miR-122a 
To study the effect of miR-122a on HCC cell proliferation,we transducted the 
constructed lentiviral vector as well as the chemically synthesized mir-122a mimics 
into HepG2 cells in which the expression level of miR-122a is undetectable and used 
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MTT assay to observe the cell growth. Figure 5.1 shows the MTT assay results.We 
can see that ectopic overexpression of miR-122a by both means could inhibit HepG2 
cell proliferation. 
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Figure 5.1 The effect ofmiR-122a on HepG2 cell proIiferation.(A). 
Ectopic expression of miR-122a by mimics inhibits HepG2 cell 
growth.5 X 10^  cells/well were seeded into 96-well plate one day before 
transfection, MTT assay was carried out one day after transfection and 
continuously for 6 days. (B). Ectopic expression of miR-122a by 
Lentiviral vector LUNIG-mir-122a inhibits HepG2 cell growth.Cells 
were transducted with lentiviral vector 2 days before seeding,then 5 X 
10^ cells/well were seeded into 96-well plate,MTT assay was carried 
out one day after seeding and continuously for 6 days. 
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In consistent with the MTT results,changes in cell morphology were also 
observed.Figure 5.2 shows the morphological change of HepG2 cells after 
transduction with lentiviral vector.We can see that compared to the controls,cells 
transducted with miR-122a expressing vector detached from the well turning 
round,and the cell number greatly decreased. 
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Figure 5.2 Effect of miR-122a on morphological change of HepG2 cells.Figure A 
corresponds to HepG2 cells with no treatment. Cells in figure B were transducted 
with the control lentiviral vector LUNIG-Luc,and figure C shows the cells 
transducted with LUNIG-miR-122a. Pictures were taken under a phase-contrast 
microscope 5 days after transduction at 100 X magnification. 
Since we have observed cell growth inhibition caused by overexpression of 
miR-122a,further we want to see whether it can induce apoptosis of the cells.Figure 
5.3 shows the DAPI staining results. Staining of the transducted cells with DAPI 
revealed nuclear chromatin condensation and nuclear fragmentation suggesting the 
overexpression of miR-122a has the ability to induce apoptosis in HepG2 cells. 
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Figure 5.3 Appearance of HepG2 cells visualized by fluorescence microscope 
after staining with DAPI. Figure A shows the cells with no treatment and cells in 
figure B were transducted with LUNIG-miR-122a. Pictures were taken at 200 X 
magnification under a fluorescence microscope 3 days after transduction. Potential 
apoptotic nuclei are indicated by white arrows. 
miR-122a is reported to modulate cyclin G1 expression in several HCC-derived 
cell lines by Laura Gramantieri,et al.In their study, an inverse correlation between 
miR-122a and cyclin G1 expression has been observed in primary liver carcinomas^. 
As we know, deregulation of cyclin G1 is associated with genomic instability^^, and 
21 22 23 
increased cyclin G1 levels have been described in several carcinomas ’ ’ . 
Moreover,there's evidence showing that suppression of cyclin G1 results in the 
inhibition of tumor growth through a reduction of proliferation and induction of 
apoptosis24，25 of which the phenotypic changes have been observed in our study. 
Although our further study didn't show obvious downregulation of cyclin G1 protein 
in HepG2 cells after miR-122a overexpression(data not shown), we infer that the cell 
growth inhibition and apoptosis observed in our case maybe result from the 
deregulation of genes with similar function modulated by miR-122a. 
5.3.2 miR-122a target prediction using bioinformatic approaches 
To begin unraveling the potential role of miR-122a in hepatocarcinogenesis, we 
used two algorithms,TargetScan (http ://www. targetscan.org) ^  ^ '' ^ ^  and Pic 
Tar(http://pictar.bio.nyu.edu)i3’ to predict its putative protein-coding gene targets. 
Both of the algorithms look for perfect matches between the mRNA target region and 
the 5' 'seed region’ of the miRNA,based on homology and structural criteria 
including sequence complementarity,stability of the RNA 一 RNA duplex, target-site 
conservation across species and the presence of multiple target sites in the same 
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gene26. Results of the separate analysis are shown in APPENDIX in which 140 and 
161 targets were predicted by Target Scan and Pic Tar respectively. It's reported that 
using combinations of two or more of the algorithms increased the number of known 
targets predicted to up to 72.6% (100% of conserved targets)^^,so in our study we 
intersected the targets commonly predicted by Target Scan and Pic Tar using 
MatchMiner (http: // discover, nci.nih. gov/ matchminer/ MatchMiner Merge.jsp/) 
for a higher rate of true-positive prediction.. Table 5.1 shows the results analysed by 
MatchMiner in which 98 common tagets have been reported. 
Index Function Input Input 
4895 Matched Records DDR2 NM_006182 
65696 Matched Records MIPOLl NM_138731 
5007 Matched Records P4HA1 NM_000917 
96772 Matched Records C9orf25 NM_147202 
9 3 ^ Matched Records HAND2 N M一 0 2 1 9 7 3 
Matched Records hTfO NM_005318 
72897 Matched Records LOG 152485 NM_178835 
33020 Matched Records TMEM32 NM_173470 
11790 Matched Records DICERl NM_030621 
11790 Matched Records DICERl NM_177438 
4132 Matched Records MARKl NM_018650 
Matched Records OCLN NM—002538 
Matched Records GYSl NM_002103 
f m Matched Records D ^ NM_001938 
1 1 1 5 4 8 Matched Records SLC25A34 N M一 2 0 7 3 4 8 
6574 Matched Records SMARCDl NM_003076 
6 5 7 4 Matched Records SMARCDl N M一1 3 9 0 7 1 
24075 Matched Records TMEM47 NM—031442 
7834 Matched Records BRPFl NM_001003694 
Matched Records BRPFl NM_004634 
2 8 ^ Matched Records GPR3 NM_005281 
13310 Matched Records SERPl NM_014445 
12444 Matched Records LRPIO NM_014045 
10350 Matched Records SLC9A6 NM_006359 
Matched Records BCL2L2 NM_004050 
100896 Matched Records YPEL4 NM_145008 
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37538 Matched Records SMYD4 NM_052928 
14326 ~ M a t c h e d Records SENPl NM_014554 
19493 Matched Records SLC39A8 NM_022154 
9865 Matched Records RODl NM_005156 
10535 Matched Records CTCF NM_006565 
587 ~ M a t c h e d Records BCAT2 NM_001190 
7770 Matched Records LUZPl NM_033631 
\73S Matched Records DLG4 NM_001365 
14518 Matched Records MINKl NM_015716 
14518 Matched Records MINKl NM—153827 
14518 Matched Records MINKl NM_170663 
^ Matched Records ALDOA NM—000034 
^ Matched Records ALDOA NM—184043 
m Matched Records ALDOA NM一 1 8 4 0 4 1 
12424 Matched Records TBCIDIOB NM_015527 
20653 Matched Records FUNDC2 NM_023934 
12818 Matched Records EIF2C1 NM_012199 
10528 Matched Records KHDRBSl NM_006559 
93213 Matched Records DAND5 NM_152654 
13248 Matched Records KCNH5 NM_172375 
576 Matched Records BAI2 NM—001703 
2 1 0 8 0 Matched Records GPR172A N M 一 0 2 4 5 3 1 
3 1 ^ Matched Records HNRPU N M _ 0 3 1 8 4 4 
Matched Records HNRPU N M _ 0 0 4 5 0 1 
2 4 4 3 1 Matched Records MAFl N M 一 0 3 2 2 7 2 
1 0 3 2 2 Matched Records VAV3 N M 一 0 0 6 1 1 3 
94M Matched Records CDC42BPB N M —0 0 6 0 3 5 
^ Matched Records CALM3 N M _ 0 0 5 1 8 4 
3 7 7 5 Matched Records KCNN3 N M _ 0 0 2 2 4 9 
3f75 Matched Records KCNN3 N M _ 1 7 0 7 8 2 
8 6 2 4 Matched Records S I X 16 N M _ 0 0 3 7 6 3 
Matched Records STX16 N M —0 0 1 0 0 1 4 3 3 
7 7 5 8 Matched Records MAP3K12 N M _ 0 0 6 3 0 1 
Matched Records STK24 N M 一 0 0 3 5 7 6 
3 3 3 2 8 Matched Records FOXP2 N M _ 1 4 8 8 9 9 
3 3 3 2 8 Matched Records F0XP2 N M _ 0 1 4 4 9 1 
3 3 3 2 8 Matched Records FOXP2 N M J 4 8 8 9 8 
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33328 Matched Records F0XP2 NM—148900 
64609 Matched Records SLC2A14 NM_153449 
Matched Records RAD21 NM—006265 
18041 Matched Records ZBTB4 NM—020899 
6 4 ^ Matched Records SLC2A3 NM_153449 
Matched Records SLC2A3 NM_006931 
6 4 ^ Matched Records SLC1A5 NM—005628 
^ Matched Records SLC4A3 NM—005070 
^ Matched Records SLC4A3 NM—201574 
18791 Matched Records BACH2 NM一021813 
13228 Matched Records TMEM28 NM_015686 
11297 Matched Records WDR47 NM一014969 
71607 Matched Records CCNYLl NM_152523 
Matched Records HDAC4 NM一006037 
19659 Matched Records CPEBl NM_030594 
Matched Records SLC7A1 NM—003045 
8 7 ^ Matched Records IQGAPl NM一003 870 
9397 Matched Records NPEPPS NM一006310 
3 5 ^ Matched Records ILIRN NM一173843 
Matched Records ILIRN NM—000577 
3550 Matched Records ILIRN NM—173842 
Matched Records ILIRN NM_173841 
14999 Matched Records CD320 NM—016579 
13379 Matched Records TNRC6A NM一014494 
Matched Records FUT8 NM_178157 
Matched Records FUT8 NM一 178156 
2 5 n Matched Records FUT8 NM—178155 
Matched Records FUT8 NM_178154 
Matched Records FUT8 NM_004480 
16923 Matched Records C9orfB6 NM_024718 
9 7 ^ Matched Records G3BP2 NM_012297 
9782 Matched Records G3BP2 NM_203505 
9 7 ^ Matched Records G3BP2 NM—203504 
29964 Matched Records CCDC97 NM_052848 
22505 Matched Records SLC05A1 NM_030958 
53548 Matched Records GNPDA2 NM_138335 
Matched Records PAK3 NM—002578 
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4208 Matched Records MAP3K3 NM_203351 
4208 Matched Records MAP3K3 NM—002401 
29 ~ M a t c h e d Records ABR NM一001092 
29 ~ M a t c h e d Records ABR NM_021962 
5788 Matched Records PURB NM—033224 
11305 Matched Records MAPREl NM_012325 
104579 ~ M a t c h e d Records VGLL2 NM_153453 
104579 Matched Records VGLL2 NM_182645 
14813 Matched Records APHIA NM一016022 
20952 Matched Records BHLHB3 NM_030762 
16864 Matched Records ZDHHC7 NM_017740 
Matched Records S ^ NM_003110 
15839 Matched Records FLJ20273 NM—019027 
16305 Matched Records GPR172B NM_017986 
22444 Matched Records ANKRD13C NM_030816 
i m Matched Records TSC22D3 NM_004089 
[ m Matched Records TSC22D3 NM—198057 
10585 Matched Records NFAT5 NM_173214 
10585 Matched Records NFAT5 NM_138713 
10585 Matched Records NFAT5 NM_006599 
10585 Matched Records NFAT5 NM_138714 
Matched Records LRRC14 NM_014665 
Matched Records ^ NM_198324 
Matched Records ^ NM_004077 
^ Matched Records CCNGl NM_l 99246 
^ Matched Records CCNGl NM_004060 
4 1 ^ Matched Records MBNLl NM_207292 
Matched Records MBNLl NM—207294 
4T47 Matched Records MBNLl NM_207295 
4 1 ^ Matched Records MBNLl NM_207293 
41^7 Matched Records MBNLl NM_207296 
4T?7 Matched Records MBNLl NM—021038 
4T47 Matched Records MBNLl NM_207297 
17283 Matched Records MOSPDl NM_019556 
2050 Matched Records ETO NM—000799 
10774 Matched Records PAPOLA NM_032632 
Matched Records LAMCl NM_002293 
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Table 5.1 Commonly predicted miR-122a targets by Target Scan and PicTar. 
Data was analysed by Matchminer (http://discover.nci.nih.gov/ matchminer / Match 
MinerMerge.jsp). “1st Input "corresponds to the results obtained by Target Scan of 
which the gene identifier is gene symbol, and "2nd Input" corresponds to the results 
obtained by Pic Tar of which the gene identifier is the GenBank Accession Number. 
5.3.3 Experimental validation of miR-122a targets by proteomics approach 
Since target prediction by bioinformatic approach tends to cause a relatively 
higher level of both false-positive and false-negative results,we further turned to 
two-dimensional gel electrophoresis, the leading tool in proteomics research,for 
experimental validation of the predicted miRNA targets. The changes at protein level 
were compared between HepG2 cells transducted with control lentiviral vector 
LUNIG-Luc and cells transducted with the miR-122a expressing vector. 
Silver-stained 2-DE gel of proteins expressed by HepG2 cells with above treatment 
are presented in .Figure 5.4. The raw images were digitalized using a scanner 
(GS-800 calibrated densitometer, Bio-Rad) and Quantity One software (Bio-Rad). 
The images were further analyzed using PDQuest (version 8.0, Bio-Rad), protein 
spots with at least 3-fold change were arrowed and numbered in Figure 5.4 A and B.. 
These spots were picked out for protein identification using MALDI-TOF MS and 
the results were shown in Table 5.2.Among the identified proteins, two of them have 
aroused our interest,they were proteasome activator subunit 1 isoform 1 (PA28alpha) 
and beta polypeptide 2-like 1 (GNB2Ll).The two proteins were reported to be 
downregulated in HCCs, and involved in the onset of hepatocarcinogenesis while 
they were found to be upregulated in miR-122a treated HCC cells.These suggest 
miR-122a may take effect through the regulation of these proteins which needs 
further confirmation by other means,ie. western blot. 
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Figure 5.4 (A) Representative 2-DE map of proteins of HepG2 cells treated 
with LUNIG-miR-122a,the miR-122a expressing lentiviral vector. 9 protein 
spots with at least 3-fold change compared to the control gel have been 
arrowed and numbered.. 
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Figure 5.4 (A) Representative 2-DE map of proteins of HepG2 cells treated 
with LUNIG-Luc,the control lentiviral vector. 7 differentially expressed 
proteins (spots) with at least 3-fold change have been arrowed and numbered.. 
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Accession No. Protein Name MW(Da) PI Score 
gi|14595132 Raichu404X 84962 7 m 
gi|50592988 ubiquinol-cytochrome c 48412.9 9 
reductase core protein II 
gi|5031753 Heterogeneousnuclear 49198.4 6 392 
ribonucleoprotein HI 
gi|5453549 thioredoxin peroxidase 30520.8 6 304 
gi|4503143 Cathepsin D preproprotein 44523.6 2 ^ 
gi|5453990 proteasome activator subunit 28705 6 1 1 4 ~ 
1 isoform 1 
gi|35053 uracil DNA glycosylase 35470.1 8 ^ 
gi|24234699 keratin 19 44079.1 5 418 
gi|296736 macropain subunit iota 24564.3 6 73 
gi|5453854 poly(rC) binding protein 1 37502 7 343 
gi|5174447 guanine nucleotide binding 3 5 0 5 4 . 6 8 ~ 
protein (G protein), beta 
polypeptide 2-like 1 
Table 5.2 Proteins identified to be changed significantly between HepG2 cells 
treated with LUNIG-luc and LUNIG-miR-122a respectively by MALDI-TOF 
MS. 
5.4 Conclusion 
Ectopic overexpression of miR-122a can inhibit cell growth and induce 
apoptosis in HepG2 cells suggesting a good candidate for the miRNA-mediated 
therapy. To begin unraveling the potential role of miR-122a in hepatocarcinogenesis, 
we utilized bioinformatic approaches for target prediction,and 98 potential targets 
have been identified by both Target Scan and Pic Tar,two different algorithms 
reported to predicte the highest percentage of experimentally validated miRNA 
targets. We further turned to two-dimensional gel electrophoresis for experimental 
validation of the predicted miRNA targets. 16 differentially expressed proteins (spots) 
with at least 3-fold change have been found between HepG2 cells transducted with 
control lentiviral vector LUNIG-Luc and cells transducted with the miR-122a 
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expressing vector. Identification of the proteins by MALDI-TOF MS revealed eleven 
differentially expressed proteins, among which proteasome activator subunit 1 
isoform 1 (PA28alpha) and beta polypeptide 2-like 1 (GNB2L1) were upregulated in 
miR-122a treated HCC cells.Since they are reported to be downregulated in HCCs 
and involved in the onset of hepatocarcinogenesis,the phenotype change of HepG2 
caused by overexpression of miR-122a may take effect through these two proteins. 
That is, PA28alpha and GNB2L1 may present two potential targets for miR-122a 
• which will be further confirmed by other means,ie. western blot. 
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Appendix 
miR-122a target prediction by Target Scan 
Target gene Gene name 
CLIC4 chloride intracellular channel 4 
SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 1 
CUTLl cut-like 1, CCAAT displacement protein (Drosophila) 
P4HA1 procollagen-proline, 2-oxogIutarate 4-dioxygenase 
(proline 4-hydroxylase)，alpha polypeptide I 
CLIC5 chloride intracellular channel 5 
SLC05A1 solute carrier organic anion transporter family,member 5A1 
OCLN occludin 
MIPOLl mirror-image Polydactyly 1 
MAP3K12 mitogen-activated protein kinase kinase kinase 12 
CCNGl cyclin G1 
BAI2 brain-specific angiogenesis inhibitor 2 
HNRPU heterogeneous nuclear ribonucleoprotein U 
(scaffold attachment factor A) 
TBCIDIOB TBCl domain family, member lOB 
GNPDA2 glucosamine-6-phosphate deaminase 2 
FUNDC2 FUN 14 domain containing 2 
LOC388965 similar to hepatitis C virus core-binding protein 6; 
cervical cancer oncogene 3 
GALC galactosylceramidase 
NPEPPS aminopeptidase puromycin sensitive 
GYS1 glycogen synthase 1 (muscle) 
SLC25A34 solute carrier family 25，member 34 
EFHA2 EF-hand domain family, member A2 
C9orf86 chromosome 9 open reading frame 86 
LOG 150084 hypothetical protein LOCI50084 
MAP3K2 mitogen-activated protein kinase kinase kinase 2 
WDR47 WD repeat domain 47 
BRPFl bromodomain and PHD finger containing, 1 
SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 
TNRC6A trinucleotide repeat containing 6A 
GPR172A G protein-coupled receptor 172A 
FKBP5 FK506 binding protein 5 
LA MCI laminin, gamma 1 (formerly LAMB2) 
PAPOLA poly(A) polymerase alpha 
IQGAPl IQ motif containing GTPase activating protein 1 
GRAMD3 GRAM domain containing 3 
ANKRD13C ankyrin repeat domain 13C 
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CPEB1 cytoplasmic polyadenylation element binding protein 1 
LRPIO low density lipoprotein receptor-related protein 10 
GTF3C2 general transcription factor IIIC，polypeptide 2,beta llOkDa 
DLG2 discs, large homolog 2, chapsyn-110 (Drosophila) 
RODl RODl regulator of differentiation 1 (S. pombe) 
CS citrate synthase 
TMEM32 transmembrane protein 32 
BHLHB3 basic helix-loop-helix domain containing, class B, 3 
MBNLl muscleblind-like (Drosophila) 
SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger),member 6 
GPR172B G protein-coupled receptor 172B 
DICER 1 Dicer 1, Dcr-1 homolog (Drosophila) 
RAVER 1 ribonucleoprotein, PTB-binding 1 ‘ 
MOSPDl motile sperm domain containing 1 
VAV3 vav 3 oncogene 
MARKl MAP/microtubule affinity-regulating kinase 1 
STK24 serine/threonine kinase 24 (STE20 homolog, yeast) ‘ 
BRWDl bromodomain and WD repeat domain containing 1 
SLC39A8 solute carrier family 39 (zinc transporter), members 
SORCS1 sortilin-related VPS 10 domain containing receptor 1 
CD320 CD320 molecule ‘ 
EPO erythropoietin 
LOG 152485 hypothetical protein LOCI52485 ‘ 
YPEL4 yippee-like 4 (Drosophila) 
STX16 syntaxin 16 “ 
ABR active BCR-related gene 
0 R C 2 L origin recognition complex, subunit 2-like (yeast) 
ALDOA aldolase A, fructose-bisphosphate 
FOXP2 forkhead box P2 
MAPREl microtubule-associated protein, RP/EB family,member 1 
CCNYLl cyclin Y-like 1 
SLC4A3 solute carrier family 4, anion exchanger, member 3 
CCDC6 coiled-coil domain containing 6 
BACH2 BTB and CNC homology 1, basic leucine zipper transcription 
factor 2 
PAK3 p21 (CDKNlA)-activated kinase 3 
A D A M 10 A D A M metallopeptidase domain 10 
MAFl MAFl homolog (S. cerevisiae) 
SPTLC3 serine palmitoyltransferase, long chain base subunit 3 
NFAT5 nuclear factor of activated T-cells 5,tonicity-responsive 
TMEM47 transmembrane protein 47 
F 0 X 0 3 A forkhead box 0 3 A 
MAP3K3 mitogen-activated protein kinase kinase kinase 3 
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KHDRBS1 KH domain containing, RNA binding,signal transduction 
associated 1 
C9orf25 chromosome 9 open reading frame 25 
CA10 carbonic anhydrase X 
FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 
MSN moesin 
DDR2 discoidin domain receptor family, member 2 
BAGE4 B melanoma antigen family, member 4 
BAGE5 B melanoma antigen family, member 5 
SERPl stress-associated endoplasmic reticulum protein 1 
FLJ20273 RNA-binding protein 
ILIRN interleukin 1 receptor antagonist 
HP 1BP3 heterochromatin protein 1，binding protein 3 
EIF2C1 eukaryotic translation initiation factor 2C, I 
BAGE3 B melanoma antigen family, member 3 
BAGE2 B melanoma antigen family, member 2 
DRl down-regulator of transcription 1, TBP-binding 
(negative cofactor 2) 
DAND5 DAN domain family, member 5 
NEGRI neuronal growth regulator 1 
SMYD4 SET and MYND domain containing 4 ‘ 
PURB purine-rich element binding protein B 
RAD21 RAD21 homolog (S. pombe) “ 
CALM3 calmodulin 3 (phosphorylase kinase, delta) 
HIFO HI histone family, member 0 
WARS tryptophanyl-tRNA synthetase 
KCNH5 potassium voltage-gated channel, subfamily H (eag-related), member 5 
CTCF CCCTC-binding factor (zinc finger protein) ‘ 
TCBA1 T-cell lymphoma breakpoint associated target 1 
CCDC97 coiled-coil domain containing 97 
SLC2A14 solute carrier family 2 (facilitated glucose transporter), member 14 
CDC42BPB CDC42 binding protein kinase beta (DMPK-like) 
BCAT2 branched chain aminotransferase 2, mitochondrial 
BIRC4 baculoviral lAP repeat-containing 4 
SMARCDl SWI/SNF related, matrix associated,actin dependent ‘ 
regulator of chromatin, subfamily d, member 1 
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 
H A N D 2 heart and neural crest derivatives expressed 2 “ 
SRF serum response factor (c-fos serum response 
element-binding transcription factor) 
MLLTl myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 1 
IHH Indian hedgehog homolog (Drosophila) 
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SENPl SUMOl/sentrin specific peptidase 1 
TMEM28 transmembrane protein 28 
BCL2L2 BCL2-like 2 
G3BP2 GTPase activating protein (SH3 domain)binciing protein2 
IGFIR insulin-like growth factor 1 receptor 
MECP2 methyl CpG binding protein 2 (Rett syndrome) 
LRRC14 leucine rich repeat containing 14 
TSC22D3 TSC22 domain family, member 3 
MEF2D MADS box transcription enhancer factor 2, 
polypeptide D (myocyte enhancer factor 2D) 
ZBTB4 zinc finger and BTB domain containing 4 
VGLL2 vestigial like 2 (Drosophila) ‘ 
LUZPl leucine zipper protein 1 
SP2 Sp2 transcription factor 
GPR3 G protein-coupled receptor 3 
MINKl misshapen-like kinase 1 (zebrafish) 
CCRN4L CCR4 carbon catabolite repression 4-like (S.cerevisiae) 
DLG4 discs, large homolog 4 (Drosophila) 
SNIP SNAP25-interacting protein 
APHIA anterior pharynx defective 1 homolog A (C. elegans) 
B4GALT2 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,polypeptide 2 
ZDHHC7 zinc finger, DHHC-type containing 7 
HDAC4 histone deacetylase 4 
KCNN3 potassium intermediate/small conductance calcium-activated channel 
subfamily N, member 3 
T N P 0 3 transportin 3 
SNX13 sorting nexin 13 
miR-122a target prediction by Pic Tar 
Refseq Id Annotation 
NM_002103 Homo sapiens glycogen synthase 1 (muscle) (GYSl) , mRNA. 
NM_005628 Homo sapiens solute carrier family 1 (neutral amino acid transporter), 
— member 5 (SLC1A5), mRNA. 
NM_016579 Homo sapiens 8D6 antigen (8D6A), mRNA. 
NM—015343 Homo sapiens dullard homolog (Xenopus laevis), mRNA. 
NM—014030 Homo sapiens G protein-coupled receptor kinase interactorl ,mRNA. 
NM一014969 Homo sapiens WD repeat domain 47 (WDR47), mRNA. 
NM_139125 Homo sapiens mannan-binding lectin serine protease 1 
— ( M A S P l i transcript variant 2，mRNA. 
NM—006182 Homo sapiens discoidin domain receptor family, member 2’ mRNA. 
NM_207348 Homo sapiens hypothetical protein LOC284723, mRNA. 
NM_003870 Homo sapiens IQ motif containing GTPase activating protein 1, 
— mRNA. 
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NM一003076 Homo sapiens SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin,subfamily d, member 1 
(SMARCDl),transcript variant 1，mRNA. 
NM—139071 Homo sapiens SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily d, member 1 
(SMARCDl),transcript variant 2, mRNA. 
NM_207292 Homo sapiens muscleblind-like (Drosophila)transcript variant 2, 
- mRNA. 
NM_207294 Homo sapiens muscleblind-like (Drosophila)transcript variant 4， 
- mRNA. 
NM一207295 Homo sapiens muscleblind-like (Drosophila)transcript variant 5, 
— mRNA. 
NM一207293 Homo sapiens muscleblind-like (Drosophila)transcript variant 3， 
— mRNA. 
NM—207296 Homo sapiens muscleblind-like (Drosophila)transcript variant 6， 
— mRNA. 
NM_021038 Homo sapiens muscleblind-like (Drosophila)transcript variant 1, 
- mRNA. 
NM_207297 Homo sapiens muscleblind-like (Drosophila)transcript variant 7, 
- mRNA. 
NM_178157 Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 
(FUT8), transcript variant 5, mRNA. 
NM_178156 Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 
_ (FUT8), transcript variant 3，mRNA. 
NM_178155 Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 
“ (FUT8), transcript variant 1, mRNA. 
NM_178154 Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 
— (FUT8), transcript variant 2, mRNA. 
NM_004480 Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 
_ (FUT8), transcript variant 4’ mRNA. 
NM一023934 Homo sapiens FUN 14 domain containing 2 (FUNDC2), mRNA. 
NM一005184 Homo sapiens calmodulin 3 (phosphorylase kinase, delta),mRNA. 
NM_015686 Homo sapiens transmembrane protein 28 (TMEM28), mRNA. 
NM_032272 Homo sapiens homolog of yeast MAFl (MAFl) , mRNA. 
NM_024643 Homo sapiens chromosome 14 open reading frame 140,mRNA. 
NM_148899 Homo sapiens forkhead box P2 (FOXP2), transcript variant 3，mRNA. 
NM_014491 Homo sapiens forkhead box P2 (F0XP2), transcript variant 1，mRNA. 
NM_148898 Homo sapiens forkhead box P2 (F0XP2), transcript variant 2, mRNA. 
NM_148900 Homo sapiens forkhead box P2 (FOXP2), transcript variant 4，mRNA. 
NM_003045 Homo sapiens solute carrier family 7 (cationic amino acid 
transporter,y+ system), member 1 (SLC7A1), mRNA. 
NM—017986 Homo sapiens G protein-coupled receptor 172B (GPR172B), mRNA. 
NM_024531 Homo sapiens G protein-coupled receptor 172A (GPR172A), mRNA. 
NM_203351 Homo sapiens mitogen-activated protein kinase kinase kinase 3 
“ (MAP3K3), transcript variant 1，mRNA. 
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NM_031844 Homo sapiens heterogeneous nuclear ribonucleoprotein U (scaffold 
attachment factor A) (HNRPU), transcript variant 1，mRNA. 
NM一002401 Homo sapiens mitogen-activated protein kinase kinase kinase 3 
(MAP3K3), transcript variant 2，mRNA. 
NM—004501 Homo sapiens heterogeneous nuclear ribonucleoprotein U 
(scaffold attachment factor A) (HNRPU), transcript variant 2, mRNA. 
NM一024774 Homo sapiens hypothetical protein FLJ21924 (FLJ21924), mRNA. 
NM_000034 Homo sapiens aldolaseAfructose-bisphosphate,transcript 
variant 1 mRNA 
NM—184043 Homo sapiens aldolase A, fructose-bisphosphate (ALDOA), 
transcript variant 3’ mRNA. 
NM一184041 Homo sapiens aldolase A, fructose-bisphosphate (ALDOA), 
transcript variant 2, mRNA. 
NM_002293 Homo sapiens laminin, gamma 1 (formerly LAMB2) (LAMCl), 
- mRNA. 
NM一030816 Homo sapiens hypothetical protein DKFZp566D 1346, mRNA. 
NM_001703 Homo sapiens brain-specific angiogenesis inhibitor 2 (BAI2), mRNA. 
NM_017740 Homo sapiens zinc finger, DHHC domain containing 7,mRNA. 
N M 一 0 0 5 0 7 0 Homo sapiens solute carrier family 4, anion exchanger, 
members,mRNA. 
N M 一 2 0 1 5 7 4 Homo sapiens solute carrier family 4, anion exchanger, 
members,mRNA. 
NM_001938 Homo sapiens down-regulator of transcription 1, TBP-binding 
“ (negative cofactor 2) (DRl) , mRNA. 
NM_005156 Homo sapiens ROD 1 regulator of differentiation 1，mRNA. 
NM_002538 Homo sapiens occludin (OCLN), mRNA. 
NM_021973 Homo sapiens heart and neural crest derivatives expressed 2，mRNA. 
NM—138335 Homo sapiens glucosamine-6-phosphate deaminase 2,mRNA. 
NM—006559 Homo sapiens KH domain containing, RNA binding, signal 
一 transduction associated 1 (KHDRBSl) , mRNA. 
NM_002249 Homo sapiens potassium intermediate/small conductance 
calcium-activated channel, subfamily N, member 3,transcript variant 
1 ,mRNA. 
NM—170782 Homo sapiens potassium intermediate/small conductance 
calcium-activated channel, subfamily N, member 3,transcript variant 
2, mRNA. 
NM一030958 Homo sapiens solute carrier organic anion transporter family, member 
- 5A1 (SLC05A1) , mRNA. 
NM_015527 Homo sapiens DKFZP434P1750 protein (DKFZP434P1750), mRNA. 
NM—134264 Homo sapiens WD repeat and SOCS box-containing 1 (WSBl) , 
transcript variant 3，mRNA. 
NM_153453 Homo sapiens vestigial like 2 (Drosophila) ,transcript variant 2, 
mRNA. 
NM_182645 Homo sapiens vestigial like 2 (Drosophila), transcript variant 1， 
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mRNA. ‘ 
NM_002578 Homo sapiens p21 (CDKNlA)-activated kinase 3 (PAK3), mRNA. 
NM_000917 Homo sapiens procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hyclroxylase), alpha polypeptide I (P4HA1), mRNA. 
NM_033631 Homo sapiens leucine zipper protein 1 (LUZPl) , mRNA. 
NM—030594 Homo sapiens cytoplasmic polyadenylation element binding 
protein 1,mRNA. 
NM_006265 Homo sapiens RAD21 homolog (S. pombe) (RAD21), mRNA. 
NM—006301 Homo sapiens mitogen-activated protein kinase kinase 
— kinase 12,mRNA. 
NM_175892 Homo sapiens hypothetical protein FLJ37266 (FLJ37266), mRNA. 
NM一005318 Homo sapiens HI histone family, member 0 (HIFO), mRNA. 
NM_024718 Homo sapiens chromosome 9 open reading frame 86 (C9orf86), 
“ mRNA. 
NM一030762 Homo sapiens basic helix-loop-helix domain containing, class B, 
— 3,mRNA. 
NM_138731 Homo sapiens mirror-image Polydactyly 1 (MIPOLl), mRNA. 
N M - 0 2 1 8 1 3 Homo sapiens BTB and CNC homology 1, basic leucine zipper 
_ transcription factor 2 (BACH2)，mRNA. 
NM一052928 Homo sapiens SET and M Y N D domain containing 4 (SMYD4), 
— mRNA. 
NM_022154 Homo sapiens solute carrier family 39 (zinc transporter), member 8， 
— mRNA. 
N M J 52523 Homo sapiens hypothetical protein FLJ40432 (FLJ40432), mRNA. 
NM—020899 Homo sapiens zinc finger and BTB domain containing 4 (ZBTB4)’ 
— mRNA. 
NM_001190 Homo sapiens branched chain aminotransferase 2, 
mitochondrial,mRNA. 
NM_199246 Homo sapiens cyclin G1 (CCNGl) , transcript variant 2, mRNA. 
NM_004060 Homo sapiens cyclin G1 (CCNGl) , transcript variant 1’ mRNA. 
NM—014045 Homo sapiens low density lipoprotein receptor-related protein 10， 
— mRNA. 
N M _ 0 0 1 0 0 3 6 9 4 H o m o sapiens bromodomain and PHD finger containing, I (BRPFl), 
transcript variant 1, mRNA. 
NM一004634 Homo sapiens bromodomain and PHD finger containing, 1 
一 (BRPFl),transcript variant 2，mRNA. 
NM—006565 Homo sapiens CCCTC-binding factor (zinc finger protein) (CTCF), 
— mRNA. 
NM—153449 Homo sapiens solute carrier family 2 (facilitated glucose 
transporter),member 14 (SLC2A14), mRNA. 
NM_014556 Homo sapiens Ellis van Creveld syndrome (EVC),transcript 
variant 1,mRNA. 
NM—022048 Homo sapiens casein kinase 1，gamma 1 (CSNKIGI) , mRNA. 
NM_019556 Homo sapiens motile sperm domain containing 1 (MOSPDl) , mRNA. 
NM_014445 Homo sapiens stress-associated endoplasmic reticulum protein 1， 
— mRNA. 
N M 一 0 0 4 0 8 9 Homo sapiens delta sleep inducing peptide, immunoreactor 
_ (DSIPI),transcript variant 2, mRNA. 
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NM_198057 Homo sapiens delta sleep inducing peptide, immunoreactor (DSIPI), 
transcript variant 1，mRNA. 
NM_014494 Homo sapiens trinucleotide repeat containing 6 (TNRC6), mRNA. 
NM—152470 Homo sapiens chromosome 18 open reading frame 23 (C18orf23), 
mRNA. 
NM—145008 Homo sapiens yippee-like 4 (Drosophila) (YPEL4), mRNA. 
NM一001365 Homo sapiens discs, large homolog 4 (Drosophila) (DLG4), mRNA. 
NM_000799 Homo sapiens erythropoietin (EPO), mRNA. 
NM—003576 Homo sapiens serine/threonine kinase 24 (STE20 homolog, yeast), 
I mRNA. 
NM—152654 Homo sapiens likely ortholog of mouse cerberus-like 2 (FLI38607)， 
“ mRNA. 
NM一001092 Homo sapiens active BCR-related gene (ABR), transcript variant 2， 
“ mRNA. 
NM_021962 Homo sapiens active BCR-related gene (ABR), transcript variant 1， 
— mRNA. 
NM_018650 Homo sapiens MAP/microtubule affinity-regulating kinase 1, mRNA. 
NM_016022 Homo sapiens likely ortholog of C. elegans anterior pharynx defective 
“ lA(APH-lA)，mRNA. 
NM一006180 Homo sapiens neurotrophic tyrosine kinase, receptor, type 2’ mRNA. 
NM一006359 Homo sapiens solute carrier family 9 (sodium/hydrogen exchanger), 
_ isoform 6 (SLC9A6), mRNA. 
NM_012325 Homo sapiens microtubule-associated protein, RP/EB family, 
— member 1 (MAPREl) , mRNA. 
NM—006310 Homo sapiens aminopeptidase puromycin sensitive (NPEPPS), 
— mRNA. 
NM—006931 Homo sapiens solute carrier family 2 (facilitated glucose transporter), 
— member 3 (SLC2A3), mRNA. 
NM_012297 Homo sapiens Ras-GTPase activating protein SH3 domain-binding 
protein2 (G3BP2), transcript variant 2，mRNA. 
NM_019027 Homo sapiens RNA-binding protein (FLJ20273), mRNA. 
NM_203505 Homo sapiens Ras-GTPase activating protein SH3 domain-binding 
protein2 (G3BP2), transcript variant 1, mRNA. 
NM_203504 Homo sapiens Ras-GTPase activating protein SH3 domain-binding 
protein2 (G3BP2),transcript variant 3，mRNA. 
NM—032632 Homo sapiens poly(A) polymerase alpha (PAPOLA), mRNA. 
NM_020178 Homo sapiens carbonic anhydrase X (CA 10), mRNA. 
NM一014665 Homo sapiens leucine rich repeat containing 14 (LRRC14), mRNA. 
NM_172315 Homo sapiens Meis l , myeloid ecotropic viral integration site 1 
homolog 2 (mouse) (ME1S2), transcript variant g, mRNA. 
NM_002399 Homo sapiens Meisl，myeloid ecotropic viral integration site 1 
homolog 2 (mouse) (MEIS2), transcript variant f, mRNA. 
NM一052848 Homo sapiens hypothetical protein MGC20255 (MGC20255), mRNA. 
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NM一170677 Homo sapiens Meisl , myeloid ecotropic viral integration site 1 
homolog 2 (mouse) (MEIS2), transcript variant a, mRNA. 
NM_172316 Homo sapiens Meisl , myeloid ecotropic viral integration site 1 
homolog 2 (mouse) (MEIS2), transcript variant h, mRNA. 
NM_170674 Homo sapiens Meisl，myeloid ecotropic viral integration site 1 
homolog 2 (mouse) (MEIS2), transcript variant b, mRNA. 
NM一173470 Homo sapiens transmembrane protein 32 (TMEM32), mRNA. 
NM_020149 Homo sapiens Meis l , myeloid ecotropic viral integration site 1 
homolog 2 (mouse) (MEIS2), transcript variant e, mRNA. 
NM一031442 Homo sapiens transmembrane 4 superfamily member 10，mRNA. 
NM—006113 Homo sapiens vav 3 oncogene (VAV3), mRNA. 
NM—004050 Homo sapiens BCL2-like 2 (BCL2L2), mRNA. 
NM—015716 Homo sapiens misshapen/NIK-related kinase ,transcript variant 1， 
— mRNA. 
NM_153827 Homo sapiens misshapen/NIK-related kinase,transcript variant 3, 
— mRNA. 
NM一170663 Homo sapiens misshapen/NIK-related kinase,transcript variant 2, 
— mRNA. 
NM_172375 Homo sapiens potassium voltage-gated channel, subfamily H 
(eag-related),member 5 (KCNH5), transcript variant 3, mRNA. 
NM_005281 Homo sapiens G protein-coupled receptor 3 (GPR3), mRNA. 
NM—198324 Homo sapiens citrate synthase (CS), nuclear gene encoding 
mitochondrial protein,transcript variant 2, mRNA. 
NM_004077 Homo sapiens citrate synthase (CS), nuclear gene encoding 
mitochondrial protein, transcript variant 1, mRNA. 
NM—173843 Homo sapiens interleukin 1 receptor antagonist,transcript variant 4， 
mRNA. 
NM一000577 Homo sapiens interleukin 1 receptor antagonist,transcript variant 3， 
mRNA. 
NM—173842 Homo sapiens interleukin 1 receptor antagonist,transcript variant 1, 
mRNA. 
NM_173841 Homo sapiens interleukin 1 receptor antagonist,transcript variant 2, 
mRNA. 
NM_006037 Homo sapiens histone deacetylase 4 (HDAC4), mRNA. “ 
NM_006035 Homo sapiens CDC42 binding protein kinase beta 
(DMPK-like),mRNA. 
NM_153355 Homo sapiens T-cell lymphoma breakpoint associated target 1， 
mRNA. 
NM一145734 Homo sapiens septin 3 (SEPT3)，transcript variant C, mRNA. 
NM_033224 Homo sapiens purine-rich element binding protein B (PURB), mRNA, 
NM_014554 Homo sapiens SUMOl/sentrin specific protease 1 (SENPl), mRNA. 
NM—178835 Homo sapiens hypothetical protein LOG 152485 (LOG 152485), 
— mRNA. 
NM_003763 Homo sapiens syntaxin 16 (STX16), transcript variant 2’ mRNA. 
NM—001001433 Homo sapiens syntaxin 16 ( S I X 16), transcript variant 1, mRNA. 
NM_130438 Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated 
kinase l A (DYRKIA), transcript variant 5’ mRNA. 
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NM—130437 Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated 
kinase l A (DYRKIA), transcript variant 4，mRNA. 
NM_001001434 Homo sapiens syntaxin 16 ( S I X 16), transcript variant 3，mRNA. 
NM—003110 Homo sapiens Sp2 transcription factor (SP2), mRNA. 
NM_101395 Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated 
kinase 1A (DYRKIA), transcript variant 3，mRNA. 
NM_030621 Homo sapiens Dicerl , Dcr-1 homolog,transcript variant 2, mRNA. 
NM—177438 Homo sapiens Dicerl, Dcr-1 homolog,transcript variant 1, mRNA. 
NM一173214 Homo sapiens nuclear factor of activated T-cells 5, tonicity-responsive 
(NFAT5), transcript variant 4’ mRNA. 
NM一 138713 Homo sapiens nuclear factor of activated T-cells 5, tonicity-responsive 
(NFAT5), transcript variant 2, mRNA. 
NM_006599 Homo sapiens nuclear factor of activated T-cells 5, tonicity-responsive 
(NFAT5), transcript variant 3，mRNA. 
NM_138714 Homo sapiens nuclear factor of activated T-cells 5，tonicity-responsive 
(NFAT5), transcript variant 1，mRNA. 
NM_147202 Homo sapiens chromosome 9 open reading frame 25 (C9orf25), 
mRNA. 
NM_012199 Homo sapiens eukaryotic translation initiation factor 
2C, l (EIF2Cl) ,mRNA. 
NM_148171 Homo sapiens ubiquitin associated protein 2 , transcript variant 3， 
mRNA. 
Note: Gene identifier type in Target Scan is the Gene Symbol while in Pic Tar it's the 
GenBank Accession Number. 
- 8 3 -
. . . . • • ‘. . . . . . . . • 
-r ；“ . ： • . ‘ - -• • . r - . . 
. . . . . . . . . . 
. , ‘ . . . ， . . . . . . . . • 
_ . _ . 、 . ： • . . ... 
. • - ‘‘ •>• • ‘ •• • . . ,„. • . . • • . •' • - • n- •  , • . • . • . '•； •• . , •  . . . . . . . . . . . . . .V) . •. I , , . • •'广 I ： . ‘ • . . . • - . � • - . . I , . . . 
C U H K L i b r a r i e s 
• • i l l 
004561529 
